Treatment of adults with overweight or obesity with or without weight-related comorbidities

HK40137339APending Publication Date: 2026-09-11CARMOT THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026123964
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-15
Filing Date
2026-05-26
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present disclosure provides methods of treating an overweight or obese patient with or without type 2 diabetes. The treatment comprises administration of a dual GLP-1 receptor and a GIP receptor agonist.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480033838.2 (22) Application Date 2024.05.21 (30) Priority Data 63 / 503,492 2023.05.21 US 63 / 511,858 2023.07.03 US 63 / 590,395 2023.10.13 US 63 / 648,158 2024.05.15 US (85) PCT International Application Entering National Phase Date 2025.11.20 (86) PCT International Application Application Data PCT / US2024 / 030441 2024.05.21 (87) PCT International Application Publication Data WO2024 / 243243 EN 2024.11.28 (71) Applicant: Camote Therapeutics, Inc. Address: California, USA (72) Inventors: M. Chakravarshi, A. Steinberg, Wu Jingtao, M. Elliott (74) Patent Agency: Shanghai Patent & Trademark Agency Co., Ltd. 31100 Patent Attorneys: Yang Yun, Yu Ying (51) Int.Cl. A61K 38 / 26 (2006.01) A61K 9 / 00 (2006.01) A61P 3 / 04 (2006.01) A61P 3 / 10 (2006.01) (54) Invention Title: Treatment of Overweight or Obese Adults with or Without Weight-Related Comorbidities (57) Abstract: This disclosure provides a method for treating overweight or obese patients with or without type 2 diabetes. The treatment comprises administering a dual GLP-1 receptor and GIP receptor agonist. Claims 2 pages, Description 65 pages, Sequence List (electronic publication), Drawings 29 pages, CN 121398835 A 2026.01.23 CN 1 21 39 88 35 A 1. A method for managing weight, improving glycemic control, and / or increasing insulin sensitivity in an overweight or obese adult patient in need, the method comprising administering, by subcutaneous injection, a compound of formula I or a pharmaceutically acceptable salt or ester thereof: (Formula I) [SEQ ID NO:1], wherein the compound is administered at a weight-independent dose of about 2.0 mg to about 25 mg. 2. The method of claim 1, wherein the patient has a BMI of ≥25 kg / m2, ≥27 kg / m2, ≥30 kg / m2, ≥35 kg / m2, or ≥40 kg / m2. 3. The method of claim 1, wherein the patient is obese. 4. The method of claim 3, wherein the patient does not have 25. The method of claim 3, wherein the patient has type 2 diabetes. 6. The method of any one of claims 1 to 5, wherein the patient has one or more weight-related comorbidities, optionally prediabetes, hypertension, or dyslipidemia. 7. The method of any one of claims 1 to 6, wherein the administration step is repeated weekly, every two weeks, every four weeks, or monthly. 8. The method of any one of the preceding claims, wherein the dose is about 5, 6, 7.5, 8, 12, 16, 17, 22, or 24 mg. 9. The method of any one of the preceding claims, wherein the dose is increased over a period of 3 to 30 weeks. 10. The method of claim 9, wherein the initial dose for the increase is about 5 mg or about 8 mg. 11. The method of claim 10, wherein the maximum dose for the increase is about 22 mg or 24 mg. 12. The method of any one of the preceding claims, wherein the patient receives additional treatment for overweight or obesity, optionally wherein the additional treatment is diet therapy or exercise therapy. 13. The method according to any one of the preceding claims, wherein administration of the compound causes a decrease in the patient's visceral fat and / or HbA1c levels. 14. A compound for use in the method according to any one of claims 1 to 13, wherein the compound is a compound of formula I or a pharmaceutically acceptable salt or ester thereof: (Formula I) [SEQ ID NO:1]. 15. Use of a compound for manufacturing a medicament for use in the method according to any one of claims 1 to 13, wherein the compound is a compound of formula I or a pharmaceutically acceptable salt or ester thereof: (Formula I) [SEQ ID NO:1]. 16. An article for use in the method according to any one of claims 1 to 13, wherein the article comprises one or more units of the dose. 17. The article according to claim 16, wherein the article comprises a syringe or injector, optionally a disposable syringe or injector. Claims 2 / 2 Page 3 CN 121398835 A Treatment for overweight or obese adults with or without weight-related comorbidities

[0001] Cross-reference to related applications

[0002] This application claims U.S. Application 63 / 503,492, filed May 21, 2023; filed July 3, 2023Priority claims are made to 63 / 511,858; 63 / 590,395 filed on October 13, 2023; and 63 / 648,158 filed on May 15, 2024. The contents of these priority applications are incorporated herein by reference in their entirety.

[0003] Sequence List

[0004] This application contains a sequence list which has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML copy was created on May 21, 2024, named 124921WO005.xml, and is 2,890 bytes in size. Background Art

[0005] Obesity is the most common chronic disease worldwide, affecting up to 650 million adults. Obesity is associated with many complications, including cardiovascular disease and type 2 diabetes (T2DM or T2D), thus imposing a huge health and economic burden on patients and society.

[0006] Type 2 diabetes mellitus (T2DM) is caused by insulin's inability to properly control blood glucose. This state of insulin resistance leads to the pancreas secreting more insulin, resulting in hyperinsulinemia; however, blood glucose levels remain abnormally high. Over time, this condition leads to β-cell exhaustion and insufficient insulin production, cardiovascular damage, and significantly increases the risk of heart attack, stroke, neuropathy, amputation, blindness, and kidney failure.

[0007] Obesity is a major risk factor for T2DM. Approximately 80% of patients with T2DM are overweight or obese. The relationship between obesity and T2DM is well-established, and the global obesity epidemic largely explains the exponential increase in the prevalence of T2DM in recent years. Obesity-associated prediabetes increases the risk of developing T2DM several times over. Once obesity occurs, it is generally difficult to lose weight due to complex compensatory and homeostatic mechanisms that reverse the regulation of weight.

[0008] It is becoming increasingly clear that effective diabetes treatment must address both insulin sensitivity and obesity (Khaodhiar et al., Curr Diab Rep. (2009) 9(5):348-54). Traditionally, lifestyle interventions in the form of diet, behavior, and exercise guidance have been the primary treatment for type 2 diabetes mellitus (T2DM) and obesity. Indeed, numerous studies have shown that strict calorie restriction for at least six months can reverse T2DM in many patients. However, such treatment regimens are rarely successful due to poor adherence. The most widely prescribed antidiabetic drugs (such as metformin, sulfonylureas, and dipeptidyl peptidase-4 (DPP4) inhibitors) do not cause significant weight loss and may even lead to weight gain (Azimova et al., Ochsner J. (2014) 14(4):616-32). Sodium-glucose cotransporter 2 inhibitors (e.g., empagliflozin and canagliflozin) cause 2%Up to 4% of patients experience weight loss and it is one of the few antidiabetic drugs that has shown improved cardiovascular outcomes. Several GLP-1 analogues have also been approved for the treatment of T2DM. These drugs lower blood glucose and glycated hemoglobin (HbA1c) and cause moderate weight loss, but their effectiveness is limited by gastrointestinal (GI) side effects such as nausea, vomiting, and diarrhea (Marín-Peñalver et al., World J Diabetes (2016) 7(17):354-95).

[0009] Therefore, there remains an urgent need to develop a safe, effective, and well-tolerated therapy for chronic weight management and glycemic control in overweight or obese patients with or without weight-related comorbidities such as T2DM. Specification 1 / 65 Page 4 CN 121398835 A Summary of the Invention

[0010] This disclosure provides a method for managing weight (inducing weight loss, or treating obesity or overweight), improving glycemic control and / or glucose homeostasis, and / or increasing insulin sensitivity in an overweight or obese adult patient in need of such treatment, the method comprising administering a compound of Formula I or a compound of Formula II or a pharmaceutically acceptable salt or ester thereof to the patient by subcutaneous injection:

[0011]

[0012] (Formula I) [SEQ ID NO:1] or

[0013]

[0014] (Formula II) [SEQ ID NO:1],

[0015] wherein the compound is administered at a uniform dose (i.e., a fixed dose independent of weight) of about 2.0 mg to about 25 mg (e.g., about 5 mg to about 24 mg, or about 5 mg to about 22 mg).

[0016] In some embodiments, the patient has a BMI of ≥25 kg / m2, ≥27 kg / m2, ≥30 kg / m2, ≥35 kg / m2, or ≥40 kg / m2. In some embodiments, the patient also has one or more weight-related comorbidities (e.g., diabetes, prediabetes, hypertension, or dyslipidemia). In some embodiments, the patient is an obese person with or without type 2 diabetes (T2DM). In some embodiments, the patient is obese or in the prediabetes stage.

[0017] In some embodiments, the compound is administered weekly, bi-weekly, or monthly.

[0018] In some embodiments, each dose is administered at approximately 5, 6, 7.5, 8, 12, 16, 17, 20, 22, or 24 mg of the compound.

[0019] In some embodiments, the dose of the compound is increased over a period of 3 to 30 weeks (e.g., one, two, three, four, five, or six months). In some embodiments, the starting dose for the increase is approximately 2 mg, approximately 4 mg, approximately 5 mg, or approximately 8 mg.mg. In some embodiments, the maximum dose for upregulation is about 22 mg or 24 mg.

[0020] In some embodiments, the patient receives additional therapy for overweight or obesity, optionally wherein the additional therapy is a diet therapy or exercise therapy.

[0021] The therapies described herein can cause a reduction in visceral fat and / or HbA1c levels in the treated patient.

[0022] This disclosure also provides compounds for use in the therapies, wherein the compound is a compound of formula I or formula II, or a pharmaceutically acceptable salt or ester thereof. This disclosure also provides the use of the compound in the manufacture of a medicament for use in the therapies of this disclosure. Specification 2 / 65 pages 5 CN 121398835 A

[0023] In another aspect, this disclosure provides an article of manufacture (e.g., a kit) for use in the therapies described herein, wherein the article of manufacture comprises one or more dose units of a compound. The article of manufacture may comprise a syringe or syringe, optionally comprising a disposable syringe or syringe.

[0024] Other features, objects and advantages of this disclosure will be apparent from the following detailed description. However, it should be understood that while the specific embodiments indicate the embodiments and aspects of this disclosure, they are given in an illustrative and not restrictive manner only. Various changes and modifications within the scope of this disclosure will become apparent to those skilled in the art based on the specific embodiments. Brief Description of the Drawings

[0025] Figure 1A is a graph showing Cmax (ng / mL; maximum observed concentration) for the test doses (0.5, 2, 4, 6, and 8 mg) in cohorts 1 to 5.

[0026] Figure 1B is a graph showing AUC0-t (h*ng / mL; area under the concentration-time curve from time zero to the last measurable concentration) for the test doses (0.5, 2, 4, 6, and 8 mg) in cohorts 1 to 5.

[0027] Figure 1C is a table showing preliminary PK parameters from cohorts 1 to 5. CL / F: Oral clearance; MRTlast: Mean residence time from time of administration to the last measurable concentration; t 1 / 2: Apparent (estimated) terminal elimination half-life (shown as a range from minimum to maximum); Vz / F: Terminal volume of distribution / bioavailability. All values ​​are mean ± standard deviation.

[0028] Figure 2A is a graph showing the change (%) in mean body weight (BW) from baseline, as measured over a 43-day period following once-weekly (QW) administration of placebo or CT-388 for 4 weeks: 5 / 5 / 5 / 7.5 mg (cohort 6 or “C6”); 5 / 5 / 8 / 12 mg (C7); or 5 / 8 / 12 / 12 mg (C8).

[0029] Figure 2BTo illustrate the mean change (%) in body weight from baseline, measurements were taken on day 29 after 4 weeks of QW administration of placebo (Pbo) or CT-388 as follows: 5 / 5 / 5 / 7.5 mg (C6); 5 / 5 / 8 / 12 mg (C7); or 5 / 8 / 12 / 12 mg (C8). *: p < 0.001 compared to placebo.

[0030] Figure 3 is a graph illustrating the change in waist circumference (cm), measured on day 29 after 4 weeks of QW administration of placebo (Plb) or CT-388 as follows: 5 / 5 / 5 / 7.5 mg; 5 / 5 / 8 / 12 mg; or 5 / 8 / 12 / 12 mg.

[0031] Figure 4 is a graph showing the changes in HOMA-IR (Homeostasis Model Assessment for Insulin Resistance), as measured on day 29 after 4 weeks of QW administration of placebo or CT-388 according to the following regimens: 5 / 5 / 5 / 7.5 mg; 5 / 5 / 8 / 12 mg; or 5 / 8 / 12 / 12 mg.

[0032] Figure 5 is a set of graphs showing the glucose response from baseline to day 23 in cohorts 6 to 8 compared to placebo.

[0033] Figure 6 is a set of graphs showing the insulin response from baseline to day 23 in cohorts 6 to 8 compared to placebo.

[0034] Figures 7A and 7B are related to the PK parameters of CT-388. Figure 7A is a table showing the preliminary PK parameters from cohorts 6 to 8. Tmax: Time to reach maximum concentration; Cmax: Maximum observed concentration; AUC0-t: Area under the concentration-time curve from time zero to the last measurable concentration; Cmin: Minimum observed concentration. All values ​​are mean ± standard deviation. Figure 7B is a graph showing the preliminary PK parameters.

[0035] Figure 8 shows arm 3 of the seamless phase 1 / 2 design of the CT-388-101 clinical trial, which is a first-in-human phase 1, double-blind, placebo-controlled, single-center study.

[0036] Figure 9 shows the design of the MD portion of the CT-388-101 clinical trial. Cohorts 11 and 12 are cohorts of obese patients without T2DM, and cohort 13 is cohort of obese patients with T2DM.

[0037] Figure 10 shows the subject disposal in the MD portion of the CT-388-101 clinical trial. *Adjustments include skipping doses or dose reduction; **food poisoning; ***medication holidays (bi-weekly dosing) at W23 due to BMI < 23 kg / m2.

[0038] Figure 11 shows the firstChanges in baseline-adjusted weight mean % at weeks 12 and 24. After considering the baseline effect in the MMRM model (with baseline weight as a covariate), CT-868 compared with placebo showed *p<0.05; **p<0.01; ***p<0.001.

[0039] Figure 12 shows the sensitivity analysis of changes in baseline weight and sex-adjusted weight mean % at weeks 12 and 24. After considering the baseline effect in the MMRM model (with baseline weight and sex as covariates), CT-868 compared with placebo showed *p<0.05; **p<0.01; ***p<0.001.

[0040] Figure 13 shows the MMRM model of the percentage change in patient weight over 24 weeks as mean LS ± SE.

[0041] Figure 14 shows the MMRM model of the percentage change in weight over 24 weeks in cohort 12, based on the actual final dose (22 mg vs 12 mg). After considering the baseline effect in the MMRM model (with baseline weight as a covariate), ***p<0.001 was observed when comparing CT-388 with placebo.

[0042] Figure 15 shows the percentage of participants who reached the specified weight loss threshold at week 24.

[0043] Figure 16 shows the mean change in baseline-adjusted waist circumference (WC) at weeks 12 and 24. After considering the baseline effect in the MMRM model (with baseline waist circumference as a covariate), *p<0.05; **p<0.01; ***p<0.001 was observed when comparing CT-868 with placebo.

[0044] Figures 17A and 17B show the glycemic control measures during the treatment period. Figure 17A shows the mean (SD) change of HbA1c from baseline, and Figure 17B shows the mean (SD) (%) of HbA1c.

[0045] Figure 18 shows the changes in glycemic status observed in trial participants.

[0046] Figure 19 is a study protocol showing randomized treatment groups in six arms receiving CT-388 or placebo at doses of 2, 4, 8, 12, 16, and 24 mg in obese or overweight participants with at least one weight-related comorbidity. *The goal is to administer the specified dose and upregulate it according to the specified titration path. However, flexibility is available during this upregulation period based on individual tolerability (i.e., the dose may be maintained at the same dose, downregulated, or a dosing holiday may be provided), with the goal of reaching the specified target dose by week 27 (the final upregulation point). Dashed lines indicate possible final doses that may be considered for safety reasons during the upregulation period. **At week 28Further dose escalation is not permitted after week 2; however, a dosing holiday or dose reduction may be provided if necessary (i.e., GI-related AEs, significant weight loss, BMI close to ≤22 kg / m2). ***Week 27: Final escalation point.

[0047] Figure 20 is a flowchart illustrating the management of participants with gastrointestinal (GI) symptoms.

[0048] Figure 21 is a study protocol illustrating randomized treatment groups in obese or overweight participants with type 2 diabetes, receiving doses of CT-388 or placebo at 2, 4, 8, 12, 16, and 24 mg in six arms. Detailed Description

[0049] This disclosure provides a therapy (e.g., monotherapy or adjunctive therapy) for weight management in overweight or obese adults with or without weight-related comorbidities such as T2DM. This therapy involves the administration of single-molecule agonists targeting both glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) and glucose-dependent insulinotropic peptide (GIP) receptor (GIPR). The therapy described herein induces weight loss and improves glucose homeostasis in treated subjects (both fasting and postprandial conditions).

[0050] I. Dual GLP-1R / GIPR Agonist Prescription 4 / 65 pages 7 CN 121398835 A

[0051] GLP-1 and GIP are the main incretins released by the gastrointestinal tract in response to food intake. Both hormones regulate glucose-dependent insulin secretion. GLP-1 also reduces glucagon secretion, slows gastric emptying, promotes satiety, and reduces food intake. Several GLP-1 mimics have been approved for the treatment of type 2 diabetes (T2DM), but their effectiveness is limited by gastrointestinal side effects such as nausea, vomiting, and diarrhea.

[0052] The primary function of GIP is to stimulate glucose-dependent insulin secretion. It also regulates glucagon secretion in an inverse glucose-dependent manner to prevent hypoglycemia and does not delay gastric emptying. GIP also stimulates glucose uptake in adipocytes and promotes bone strength.

[0053] The dual GLP-1R / GIPR agonist used in the therapy of this disclosure, referred to as “CT-388,” effectively activates the production of cyclic adenosine monophosphate (cAMP) but has no or minimal activity on the β-brake protein signaling pathway on GLP-1R or GIPR. That is, the agonist is completely biased toward cAMP activation on GLP-1R and GIPR, rather than partially biased (i.e., with some β-brake protein activity) or unbiased (i.e., with full β-brake protein activity). β-brake protein activates the kinase signaling pathway but also leads to the shutdown and internalization of GLP-1R and GIPR (Hsia).Curr Opin Endocrinol Diabetes Obes. (2017) 24(1):73-9). The agonist of this disclosure does not cause internalization, thereby desensitizing GLP-1R or GIPR, and thus has enhanced signal transduction efficacy.

[0054] CT-388 has the following structural formula:

[0055]

[0056] (Formula I) [SEQ ID NO:1]

[0057] The structure of CT-388 can also be described as follows:

[0058]

[0059] (Formula II) [SEQ ID NO:1]

[0060] Formula I and Formula II both refer to the same compound.

[0061] Pharmaceutically acceptable salts (e.g., sodium salts or phosphates) of the compounds described above are also within the scope of the meaning of “CT-388” herein. Pharmaceutically acceptable esters of the compounds shown above may also be used in the therapies of this disclosure.

[0062] This disclosure provides pharmaceutical compositions comprising CT-388 and pharmaceutically acceptable excipients. In some embodiments, the sole active pharmaceutical ingredient (API) of the pharmaceutical composition is a compound of formula I or a compound of formula II.

[0063] In some embodiments, CT-388 is provided as a sterile lyophilized powder that is reconstituteable into a solution suitable for subcutaneous injection. In some embodiments, CT-388 is provided as a sterile aqueous solution suitable for subcutaneous injection. For example, CT-388 may be provided at a concentration of 20 mg / mL in a sodium phosphate buffer containing mannitol at pH 7.0.

[0064] CT-388 may be well tolerated and causes fewer side effects than other incretin mimics. For example, chronic toxicology data showed that CT-388 was well tolerated in rats and monkeys with repeated administrations for 26 and 39 weeks, respectively, exceeding 100 times the pharmacologically active dose, and causing weight loss of up to 10%. Therefore, CT-388 may be an effective drug with acceptable tolerability that induces significant weight loss and helps achieve optimal glycemic control in overweight or obese adults with or without T2DM or other weight-related comorbidities. CT-388 may be used as a non-invasive alternative to bariatric surgery for weight management.

[0065] II. Patient Population

[0066] In some embodiments, patients are at least 18 years old and at most 75 years old. Exemplary patient populations suitable for treatment by the methods of this disclosure are further described below.

[0067] A. Overweight and obese adults who are otherwise healthy and obese patients with type 2 diabetes

[0068] Weight management treatments described herein may be chronic or short-term, as determined by a physician. In some embodiments, this disclosure provides a CT-388 therapy for weight management in obese or overweight adults with or without weight-related abnormalities. In some embodiments, the adult patient has one or more weight-related (treated or untreated) comorbidities (e.g., prediabetes, T2DM, hypertension, and dyslipidemia). In some embodiments, such adults are prediabetic and the therapy improves glycemic control in these adults; in a further embodiment, the prediabetic adult is obese.

[0069] In some embodiments, this disclosure provides a CT-388 therapy for weight management in obese or overweight healthy adults. Overweight or obese adults who are otherwise healthy lack any significant clinical history or active clinical manifestations of metabolic, proliferative, allergic, dermatological, liver, kidney, blood, lung, cardiovascular, gastrointestinal, neurological, or psychiatric disorders.

[0070] In some embodiments, this disclosure provides a CT-388 therapy for weight management and glycemic control in obese or overweight adults with T2DM. In some embodiments, such adults have one or more weight-related or T2DM-related (treated or untreated) comorbidities (e.g., hypertension and dyslipidemia).

[0071] In some embodiments, this disclosure provides a CT-388 therapy for glycemic control in T2DM adults who are not obese or overweight (e.g., BMI < 25 kg / m2).

[0072] As used herein, an adult is someone aged 18 years or older. In some embodiments, the therapy of this disclosure treats adults aged between 18 and 65 years (inclusive). In some embodiments, the patient is 75 years or younger (e.g., 65 years or younger, 66 years or younger, 67 years or younger, 68 years or younger, 69 years or younger, 70 years or younger, 71 years or younger, 72 years or younger, 73 years or younger, or 74 years or younger).

[0073] The health status of patients treated in the therapy of this disclosure is further described below.

[0074] 1. Overweight and Obesity

[0075] Body Mass Index (BMI) is a simple height-weight index commonly used to classify overweight and obesity in adults. It is defined as a person's weight (in kilograms) divided by the square of their height (in meters) (kg / m2). For adults, the WHO defines overweight as having a BMI of 25 to 29.9 kg / m2 and obesity as having a BMI ≥ 30 kg / m2. Obesity is generally subdivided into the following categories:

[0076] - Obesity Category I – BMI 30 to 34.9 kg / m2

[0077] - Obesity Grade II – BMI 35 to 39.9 kg / m2; and specification page 6 / 65 9 CN 121398835 A

[0078] - Obesity Grade III – BMI ≥40 kg / m2 (also known as severe, extreme, or gross obesity)

[0079] In some embodiments, the definitions of overweight and obesity in Asian and South Asian populations may be as follows:

[0080] - Overweight – BMI 23 to 24.9 kg / m2

[0081] - Obesity – BMI ≥25 kg / m2

[0082] In some embodiments, the patient to be treated herein is overweight. In other embodiments, the patient to be treated herein is obese, having Grade I, II, or III obesity.

[0083] 2. T2DM

[0084] T2DM and prediabetes can be defined by the 2022 ADA Standards of Diabetes Care (American Diabetes Association, ADA, “Standards of Medical Care in Diabetes,” Clin Diabetes (2022) 40(1):10-38). The ADA definition is shown in Table 1 below.

[0085] Table 1. Definition of Blood Glucose Status

[0086]

[0087] * FPG: Fasting blood glucose. OGTT: Oral glucose tolerance test. HbA1c: Hemoglobin IC.

[0088] In order to diagnose prediabetes or diabetes, at least one of the above tests (i.e., FPG, 2-hour post-load blood glucose, or HbA1c) needs to be abnormal (i.e., exceeding / above the normal blood glucose range / value for each corresponding test).

[0089] In some embodiments, the patient has type 2 diabetes (T2DM). In some embodiments, patients with type 2 diabetes mellitus (T2DM) have a BMI of ≥25 kg / m2, ≥27 kg / m2, ≥30 kg / m2, ≥35 kg / m2, ≥40 kg / m2, or ≥45 kg / m2. In some embodiments, patients with T2DM are not overweight or obese.

[0090] 3. Other medical conditions

[0091] In some embodiments, patients treated herein have one or more comorbidities, such as prediabetes (see above), hypertension, and dyslipidemia. Hypertension may be defined as hypertension currently treated with antihypertensive medication, or systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure (DBP) ≥80 mmHg. Dyslipidemia may be defined as dyslipidemia currently treated with lipid-lowering agents, or low-density lipoprotein (LDL) ≥160 mg / dL (4.1 mmol / L) or triglycerides ≥150 mg / dL.mg / dL (1.7 mmol / L), or high-density lipoprotein (HDL) <40 mg / dL (1.0 mmol / L) for men or <50 mg / dL (1.3 mmol / L) for women.

[0092] In some embodiments, the patients described herein are not pregnant or lactating.

[0093] In some embodiments, the patients described herein have no history of bariatric surgery or gastric banding (including LAP-BAND), any history of gastrointestinal surgery that may induce malabsorption (e.g., bowel resection), or any GI motility disorder, gastroparesis, delayed gastric emptying, inflammatory bowel disease, pancreatitis, malabsorption syndrome, chronic diarrhea, chronic constipation, or clinically significant irritable bowel syndrome. Specification 7 / 65 pages 10 CN 121398835 A

[0094] In some embodiments, the patients described herein do not have a semi-supine systolic blood pressure >160 mm Hg and / or a diastolic blood pressure >95 mm Hg.

[0095] In some embodiments, the patients described herein do not have active or untreated malignancies, or have been in remission for <5 years from clinically significant malignancies (excluding basal cell or squamous cell skin cancer, cervical cancer in situ, or prostate cancer in situ).

[0096] In some embodiments, the patients described herein have no personal or family history (first-degree relatives) of medullary thyroid carcinoma (MTC), or a genetic predisposition to MTC (i.e., thyroid C-cell hyperplasia or multiple endocrine neoplasia type 2A or 2B).

[0097] In some embodiments, the patients described herein have no history of: atopic (severe or multiple allergic manifestations) or clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post-treatment hypersensitivity; known allergy to any component of the pharmaceutical composition, GLP-1 analogs, or related compounds.

[0098] In some embodiments, the patients described herein have not used hormone replacement therapy.

[0099] In some embodiments, the patients described herein were not concurrently receiving other pharmacological therapies for obesity, including but not limited to: Saxenda® (liraglutide), Wegovy® (semagraglutide), Mounjaro® (tesipatide), Xenical® or Alli® (orlistat), Meridia® (sibutramine), Acutrim® (phenylpropanolamine), Sanorex® (maindole), Apidex® (phentermine), BELVIQ® (lorcaserin), Qsymia® (phentermine / topiramate combination), Contrave® (naltrexone / bupropion), Asenlix® (clobenzylex), Solucaps® (maindole), Redotex®(aldehydes, atropine, diazepam, norpseudoephedrine, triiodothyronine), berberine, resveratrol, other sympathomimetic agents, thyroid hormones (for non-thyroid indications), growth hormone, or any non-growth hormone supplement / replacement therapy containing unknown / unspecified amounts.

[0100] In some embodiments, the patients to be treated herein are not concurrently receiving other drugs targeting GLP-1R and / or GIPR.

[0101] B. Obese or overweight patients with at least one weight-related comorbidity

[0102] In some embodiments, the patient is at least 18 years old and at most 75 years old. In some embodiments, the patient is obese (defined as having a BMI ≥30.0 ​​kg / m2). In some embodiments, the patient is overweight (defined as having a BMI ≥27.0 and <30.0 kg / m2) and has been previously diagnosed with at least one of the following weight-related comorbidities:

[0103] a. Prediabetes, as defined according to the 2024 ADA Standards of Diabetes Care;

[0104] b. Hypertension, defined as currently being treated with antihypertensive medication, or systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg;

[0105] c. Dyslipidemia, defined as currently being treated with lipid-lowering agents, or low-density lipoprotein (LDL) ≥160 mg / dL (4.1 mmol / L) or triglycerides ≥150 mg / dL (1.7 mmol / L), or high-density lipoprotein (HDL) <40 mg / dL (1.0 mmol / L) in men or <50 mg / dL (1.3 mmol / L) in women;

[0106] d. Obstructive sleep apnea; or

[0107] e. Cardiovascular disease (e.g., ischemic cardiovascular disease, New York Heart Association (NYHA) functional class I or II heart failure)

[0108] In some embodiments, the patient has ≥ 1 self-reported failure of a weight-loss diet or exercise program.

[0109] In some embodiments, the patient does not have a history or diagnosis of any type of diabetes (e.g., type 1, type 2, pregnancy), or a history of ketoacidosis or hyperosmolar state. The patient may not have diabetes, as determined based on fasting blood glucose or HbA1c.

[0110] In some embodiments, the patient is diagnosed with prediabetes (as determined by fasting blood glucose or HbA1c levels). Such patients may not be receiving any type of glucose-lowering treatment (medications or dietary supplements), such as metformin or berberine.

[0111] In some embodiments, the patient has not undergone any type of prior obesity surgery. In some embodiments, the patient has not experienced LAP-BAND®, gastric balloon, duodenal cannulation, skin resurfacing, liposuction, or abdominoplasty.

[0112] In some embodiments, the patient does not have a known clinically significant or active gastric emptying disorder (e.g., severe gastroparesis or gastric outlet obstruction, intestinal obstruction, or any gastrointestinal (GI) motility disorder); malabsorption, including chronic constipation / diarrhea, celiac disease, inflammatory bowel disease, or bowel resection; or long-term use of medications that directly affect GI motility (e.g., anticholinergics, serotonin antagonists, or opioids).

[0113] The patient may not have chronic or acute pancreatitis. In some embodiments, the patient has no history of gallstones and / or acute cholecystitis or uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg and / or diastolic blood pressure ≥ 100 mm Hg) complications.

[0114] In some embodiments, the patient does not have congestive heart failure (e.g., NYHA functional classification III or IV congestive heart failure), myocardial infarction, cerebrovascular accident (stroke), transient ischemic attack, unstable angina, coronary artery bypass grafting, or percutaneous coronary intervention. In some embodiments, the patient has no personal or family history of long QT syndrome, a family history of sudden death of a first-degree relative (parent, sibling, or child) before age 40, or a personal history of unexplained syncope.

[0115] In some embodiments, the patient does not have uncontrolled thyroid disease (defined as active symptoms, such as palpitations, somnolence, weight gain / loss) and / or has thyroid-stimulating hormone (TSH) levels outside the normal reference range.

[0116] In obese patients, obesity may not be induced by other endocrine disorders (e.g., Cushing's syndrome, acromegaly, undertreated hypothyroidism) or diagnosed as a monogenic or syndromic form of obesity (e.g., melanocyte-stimulating hormone 4 receptor deficiency or Pu-Wei syndrome). In some embodiments, the patient has no family or personal history of medullary thyroid carcinoma, or a genetic predisposition to medullary thyroid carcinoma (i.e., thyroid C-cell hyperplasia or multiple endocrine neoplasia type 2A or 2B).

[0117] In some embodiments, the patient does not have:

[0118] a. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) > 3.0 × the upper limit of normal (ULN) of the reference range;

[0119] b. Alkaline phosphatase (ALP) > 1.5 × the ULN of the reference range;

[0120] c. Total bilirubin > 1 × the ULN of the reference range;

[0121] d. Amylase or lipase > 2 × the ULN of the reference range;

[0122] e. Calcitonin≥20 ng / L;

[0123] f. Estimated glomerular filtration rate (eGFR) <60 mL / min / 1.73 m2 as obtained by the 2021 CKD-EPI creatinine equation;

[0124] g. Fasting plasma triglycerides ≥500 mg / dL;

[0125] h. Acute or chronic viral hepatitis (determined based on the presence of hepatitis B surface antigen [HbsAg] or HCV RNA);

[0126] i. HIV antibody positive at screening;

[0127] j. Hemoglobin value <11 g / dL (male) or <10 g / dL (female);

[0128] k. White blood cell (WBC) < lower limit of normal (LLN) of the reference range; or instructions 9 / 65 page 12 CN 121398835 A

[0129] l. Platelets < lower limit of normal (LLN) of the reference range.

[0130] C. Overweight or obese patients with type 2 diabetes

[0131] In some embodiments, the patient is between 18 and 75 years of age. The patient may have a BMI ≥25.0 kg / m2. The patient may also be diagnosed with T2DM according to, for example, the World Health Organization classification. The patient's HbA1c level may be ≥7% and ≤10.5%.

[0132] In some embodiments, the patient manages their T2DM solely through diet and exercise prior to treatment. In some embodiments, the patient manages their T2DM through stable treatment with metformin, sulfonylureas, or SGLT-2 inhibitors as monotherapy or combination therapy. The patient may have ≥1 self-reported experience of diet / exercise failure.

[0133] In some embodiments, the patient does not have type 1 diabetes (T1DM) or any other type of diabetes other than T2DM. The patient may not have a history of ketosis or hyperosmolar state / coma. In some embodiments, the patient does not have proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy requiring acute treatment based on dilated fundus examination by an ophthalmologist or optometrist between screening and randomization.

[0134] The patient may not have clinically significant / active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, diabetic diarrhea).

[0135] In some embodiments, the patient has not undergone Lap-Band®, gastric balloon, duodenal cannulation, skin resurfacing, liposuction, and / or abdominoplasty.

[0136] In some embodiments, the patient does not have known clinically significant or active gastric emptying abnormalities (e.g., severe gastroparesis or gastric outlet obstruction, intestinal obstruction, or any GI motility disorder); malabsorption, including chronic constipation / diarrhea, celiac disease, inflammatory bowel disease, or bowel resection; or long-term use directly affecting...GI-mediated drugs (e.g., anticholinergics, serotonin antagonists, opioids).

[0137] The patient may not have chronic or acute pancreatitis. In some embodiments, the patient has no history of gallstones and / or acute cholecystitis or uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg) complications.

[0138] In some embodiments, the patient has no history of congestive heart failure (e.g., NYHA functional class III or IV congestive heart failure), myocardial infarction, cerebrovascular accident (stroke), transient ischemic attack, unstable angina, coronary artery bypass grafting, or percutaneous coronary intervention. In some embodiments, the patient has no personal or family history of long QT syndrome, a family history of sudden death of a first-degree relative (parent, sibling, or child) before age 40, or a personal history of unexplained syncope.

[0139] In some embodiments, the patient has no uncontrolled thyroid disease (defined as active symptoms, such as palpitations, somnolence, weight gain / loss) and / or has thyroid-stimulating hormone (TSH) levels outside the normal reference range.

[0140] In obese patients, obesity may not be induced by other endocrine disorders (e.g., Cushing's syndrome, acromegaly, undertreated hypothyroidism) or diagnosed as a monogenic or syndromic form of obesity (e.g., melanocyte-stimulating hormone 4 receptor deficiency or P.W. syndrome). In some embodiments, the patient has no family or personal history of medullary thyroid carcinoma or a genetic predisposition to medullary thyroid carcinoma (i.e., thyroid C-cell hyperplasia or multiple endocrine neoplasia type 2A or 2B).

[0141] In some embodiments, the patient does not have:

[0142] a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) >3.0 × the upper limit of normal (ULN) of the reference range;

[0143] b. Alkaline phosphatase (ALP) >1.5 × the ULN of the reference range;

[0144] c. Total bilirubin >1 × the ULN of the reference range;

[0145] d. Amylase or lipase >2 × the ULN of the reference range;

[0146] e. Calcitonin ≥20 ng / L;

[0147] f. Estimated glomerular filtration rate (eGFR) <45 mL / min / 1.73 m2, as obtained by the 2021 CKD-EPI creatinine equation;

[0148] g. Fasting plasma triglycerides ≥500 mg / dL;

[0149] h. Acute or chronic viral hepatitis (based on the presence of hepatitis B surface antigen [HbsAg] or HCV RNA)

[0150] i. HIV antibody positive at screening;

[0151] j. Hemoglobin value <11 g / dL (male) or <10 g / dL (female);

[0152] k. White blood cell (WBC) < lower limit of normal (LLN) of the reference range; or

[0153] l. Platelet count < lower limit of normal of the reference range.

[0154] III. CT-388 therapy

[0155] The pharmaceutical composition containing CT-388 may be administered subcutaneously at intervals deemed appropriate by a physician, such as every three days, every four days, every five days, every six days, weekly, every two weeks, every three weeks, every four weeks, every eight weeks, monthly or every two months. The pharmaceutical composition containing CT-388 may be administered subcutaneously by the patient (i.e., by self-administration).

[0156] In some embodiments, the pharmaceutical composition containing CT-388 is administered once weekly (QW), once every two weeks (i.e., bi-weekly or Q2W), or once monthly (QM) by subcutaneous injection at a body site (e.g., abdomen, upper arm, thigh, or buttock). In some embodiments, the pharmaceutical composition containing CT-388 is administered by subcutaneous injection at intervals (e.g., as described above) over a period of 4 to 28 weeks or longer (e.g., 6, 12, 18, or 24 months or longer). In some embodiments, the administration of the pharmaceutical composition is independent of diet.

[0157] In some embodiments, CT-388 is administered at a uniform dose of about 0.5 mg to about 30 mg (e.g., about 1 mg to about 28 mg, about 2 mg to about 27 mg, about 3 mg to about 26 mg, about 4 mg to about 25 mg, about 5 mg to about 24 mg, about 5 mg to about 22 mg, about 8 mg to about 22 mg, about 8 mg to about 24 mg, about 5 mg to about 17 mg, about 2 mg to about 16 mg, about 4 mg to about 16 mg, about 2 mg to about 20 mg, about 4 mg to about 20 mg, about 2 mg to about 24 mg, or about 4 mg to about 24 mg) to adult patients as described in this disclosure (e.g., otherwise healthy overweight or obese adult patients; overweight or obese adult patients with weight-related comorbidities but without diabetes; overweight or obese adult patients with T2DM but without complications; or patients with T2DM). Subcutaneous administration to overweight or obese adult patients with one or more complications. In some embodiments, treatment with CT-388 is initiated according to an upregulation plan, i.e., starting treatment with a low dose and gradually increasing the dose to a higher level over a period of time.The highest tolerated dose. In some embodiments, the dosage is increased in increments of 2 to 10 mg each time (e.g., in increments of 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg).

[0158] In some embodiments, the pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 0.5 mg per QW, Q2W, or QM.

[0159] In some embodiments, the pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 2 mg per QW, Q2W, or QM.

[0160] In some embodiments, the pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 4 mg per QW, Q2W, or QM.

[0161] In some embodiments, a pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 5 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0162] In some embodiments, a pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 6 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0163] In some embodiments, a pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 7.5 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0164] In some embodiments, a pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 8 mg per quarter-week (QW), quarter-week (Q2W), or quarter-week (QM).

[0165] In some embodiments, a pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 12 mg per quarter-week (QW), quarter-week (Q2W), or quarter-week (QM).

[0166] In some embodiments, a pharmaceutical composition containing CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 16 mg per quarter-week (QW), quarter-week (Q2W), or quarter-week (QM).

[0167] In some embodiments, a pharmaceutical composition containing CT-388...The pharmaceutical composition comprising CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 17 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0168] In some embodiments, the pharmaceutical composition comprising CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 20 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0169] In some embodiments, the pharmaceutical composition comprising CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 22 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0170] In some embodiments, the pharmaceutical composition comprising CT-388 is administered subcutaneously to an overweight or obese patient with or without T2DM (with or without comorbidities) at a dose of about 24 mg per quarter-week, quarter-week, or quarter-week (QW, Q2W, or QM).

[0171] In some embodiments, treatment with CT-388 is initiated according to an upregulation plan, i.e., treatment begins at a low dose and is gradually increased over a period of time to a higher or maximum tolerated dose. In some embodiments, titration occurs over a period of about 3, 4, 8, 12, 16, 20, 24, 28, or 32 weeks or longer; in further embodiments, during the titration period, the pharmaceutical composition containing CT-388 is injected in quarter-wound (QW) doses. In some embodiments, titration begins with a dose of 5 mg (starting dose) and the dose is increased in increments of 2 to 10 mg (e.g., in increments of 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg) until a dose between 7.5 mg and 24 mg (maintenance dose or maximum dose), such as 22 mg. During the titration period, patients may remain at the new dose for 1 to 10 weeks (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 weeks) to allow for acclimatization before proceeding to the next higher dose.

[0172] In some embodiments, titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following protocol:

[0173] Week 1, 5 mg;

[0174] Week 2, 5 mg;

[0175] Week 3, 5 mg; and

[0176] Week 4, 7.5 mg.

[0177] In a further embodiment, the treated patients are overweight or obese patients without weight-related comorbidities such as T2DM.

[0178] In some embodiments, titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following protocol:

[0179] Week 1, 5 mg;

[0170] Week 2, 5 mg;

[0171] Week 3, 5 mg; and

[0172] Week 4, 7.5 mg.

[0180] Week 2, 5 mg;

[0181] Week 3, 8 mg; and instruction manual, page 12 / 65, CN 121398835 A

[0182] Week 4, 12 mg.

[0183] In some embodiments, titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following scheme:

[0184] Week 1, 5 mg;

[0185] Week 2, 8 mg;

[0186] Week 3, 12 mg; and

[0187] Week 4, 12 mg.

[0188] In some embodiments, the titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following protocol:

[0189] Week 1, 8 mg;

[0190] Week 2, 8 mg;

[0191] Week 3, 12 mg; and

[0192] Week 4, 16 mg.

[0193] In some embodiments, the titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following protocol:

[0194] Week 1, 8 mg;

[0195] Week 2, 12 mg;

[0196] Week 3, 16 mg; and

[0197] Week 4, 20 mg.

[0198] In some embodiments, titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following protocol:

[0199] Week 1, 5 mg;

[0200] Week 2, 8 mg;

[0201] Week 3, 12 mg; and

[0202] Week 4, 16 mg.

[0203] In some embodiments, titration occurs over a period of 3 weeks or longer (e.g., 4 weeks) according to the following protocol:

[0204] Week 1, 5 mg;

[0205] Week 2, 5 mg;

[0206] Week 3, 5 mg; and

[0207] Week 4, 8 mg.

[0208] In a further embodiment, the treated patient is an obese patient without weight-related comorbidities such as type 2 diabetes mellitus (T2DM).

[0209] In some embodiments, the titration occurs over a period of 8 weeks or longer (e.g., 9 weeks) according to the following scheme:

[0210] Week 1, 5 mg;

[0211] Week 2, 5 mg;

[0212] Week 3, 8 mg;

[0213] Week 4, 8 mg;

[0214] Week 5, 12 mg;

[0215] Week 6, 12 mg;

[0216] Week 7

[0217] Week 8, 17 mg; and

[0218] Week 9, 22 mg.

[0219] In a further embodiment, the treated patient is an obese person with or without weight-related comorbidities such as T2DM.

[0220] In some embodiments, titration occurs over a period of 8 weeks or longer (e.g., 9 weeks) according to the following protocol:

[0221] Week 1, 8 mg;

[0222] Week 2, 8 mg;

[0223] Week 3, 8 mg;

[0224] Week 4, 8 mg;

[0225] Week 5, 16 mg;

[0226] Week 6, 16 mg;

[0227] Week 7, 16 mg;

[0228] Week 8, 16 mg; and

[0229] Week 9, 24 mg.

[0230] In a further embodiment, the treated patient is an obese patient without weight-related comorbidities such as type 2 diabetes mellitus (T2DM).

[0231] In some embodiments, titration occurs over a period of 8 weeks or longer (e.g., 9 weeks) according to the following protocol:

[0232] Week 1, 8 mg;

[0233] Week 2, 8 mg;

[0234] Week 3, 12 mg;

[0235] Week 4, 12 mg;

[0236] Week 5, 16 mg;

[0237] Week 6, 16 mg;

[0238] Week 7, 20 mg;

[0239] Week 8, 20 mg; and

[0240] Week 9, 24 mg.

[0241] In a further embodiment, the treated patient is an obese patient without weight-related comorbidities such as type 2 diabetes mellitus (T2DM).

[0242] In some embodiments, titration occurs over a period of 11 weeks or longer (e.g., 12 weeks) according to the following regimen:

[0243] 5 mg weekly from week 1 to week 3; and

[0244] 8 mg weekly from week 4 to week 9.

[0245] In a further embodiment, the patients treated are obese patients without weight-related comorbidities such as T2DM. Specification 14 / 65 pages 17 CN 121398835 A

[0246] In some embodiments, titration occurs over a period of 23 weeks or longer (e.g., 25 weeks) according to the following regimen:

[0247] 2 mg from week 1 to week 4;

[0248] 4 mg from week 5 to week 8;

[0249] 8 mg from week 9 to week 12;

[0250] 12 mg from week 13 to week 16;

[0251] Weeks 17 to 20, 16 mg;

[0252] Weeks 21 to 24, 20 mg; and

[0253] Week 25, 24 mg.

[0254] In a further embodiment, the treated patient is an obese or overweight patient with at least one weight-related complication.

[0255] In some embodiments, titration occurs over a period of 16 weeks or longer (e.g., 17 weeks) according to the following protocol:

[0256] Weeks 1 to 4, 2 mg;

[0257] Weeks 5 to 8, 4 mg;

[0258] Weeks 9 to 12, 8 mg;

[0259] Weeks 13 to 16, 12 mg; and

[0260] Week 17, 16 mg.

[0261] In a further embodiment, the treated patient is an obese or overweight patient with at least one weight-related complication.

[0262] In some embodiments, titration occurs over a period of 12 weeks or longer (e.g., 13 weeks) according to the following protocol:

[0263] Weeks 1 to 4, 2 mg;

[0264] Weeks 5 to 8, 4 mg;

[0265] Weeks 9 to 12, 8 mg; and

[0266] Week 13, 12 mg.

[0267] In a further embodiment, the treated patient is an obese or overweight patient with at least one weight-related complication.

[0268] In some embodiments, titration occurs over a period of four weeks or longer (e.g., five weeks) according to the following protocol:

[0269] Weeks 1 to 4, 4 mg; and

[0270] Week 5, 8 mg.

[0271] In a further embodiment, the treated patient is an obese or overweight patient with at least one weight-related complication.

[0272] In some embodiments, titration occurs over a period of 23 weeks or longer (e.g., 25 weeks) according to the following regimen:

[0273] Weeks 1 to 4, 2 mg;

[0274] Weeks 5 to 8, 4 mg;

[0275] Weeks 9 to 12, 8 mg;

[0276] Weeks 13 to 16, 12 mg;

[0277] Weeks 17 to 20, 16 mg;

[0278] Weeks 21 to 24, 20 mg; and

[0279] Week 25, 24 mg.

[0280] In a further embodiment, the patient being treated is an overweight or obese patient with type 2 diabetes.

[0281] In some embodiments, titration occurs over a period of 16 weeks or longer (e.g., 17 weeks) according to the following protocol:

[0282] Weeks 1 to 4, 2 mg;

[0283] Weeks 5 to 8, 4 mg;

[0284] Weeks 9 to 12, 8 mg;

[0285] Weeks 13 to 16, 12 mg; and

[0286] Week 17, 16 mg.

[0287] In a further embodiment, the treated patient is an overweight or obese patient with type 2 diabetes.

[0288] In some embodiments, titration occurs over a period of four weeks or longer (e.g., five weeks) according to the following protocol:

[0289] Weeks 1 to 4, 4 mg; and

[0290] Week 5, 8 mg.

[0291] In a further embodiment, the treated patient is an overweight or obese patient with type 2 diabetes.

[0292] In some embodiments, titration is performed according to the following regimen:

[0293] Week 1 to Week 12, 2 mg; and

[0294] Week 13, 4 mg.

[0295] In a further embodiment, the patient being treated is an overweight or obese patient with type 2 diabetes.

[0296] In some embodiments, titration is performed according to the following regimen:

[0297] Week 1 to Week 12, 4 mg; and

[0298] Week 13, 8 mg.

[0299] In a further embodiment, the patient being treated is an overweight or obese patient with type 2 diabetes.

[0300] In some embodiments, titration is performed according to the following regimen:

[0301] Week 1 to Week 4, 4 mg;

[0302] Week 5 to Week 8, 8 mg;

[0303] Week 9 to Week 12, 12 mg; and

[0304] Week 13, 16 mg.

[0305] In a further embodiment, the patient being treated is an overweight or obese patient with type 2 diabetes.

[0306] In some embodiments, titration is performed according to the following protocol:

[0307] Weeks 1 to 4, 2 mg;

[0308] Weeks 5 to 8, 4 mg;

[0309] Weeks 9 to 12, 8 mg;

[0310] Weeks 13 to 16, 12 mg;

[0311] Weeks 17 to 20, 16 mg;

[0312] Weeks 21 to 24, 20 mg; and the instruction manual, page 16 / 65, CN 121398835 A

[0313] Week 25, 24 mg.

[0314] In a further embodiment, the patient being treated is an overweight or obese patient with type 2 diabetes.

[0315] When titrating up the dose, if the dose is not tolerated at any stage, the next dose can be administered at the previously tolerated dose (i.e., down-adjustment is permitted). In some embodiments, the patient may then attempt up-adjustment at a subsequent scheduled dosing time.

[0316] In some embodiments, the pharmaceutical composition containing CT-388 is administered as an adjunct to diet and / or exercise therapy to an overweight or obese patient with or without weight-related comorbidities (e.g., T2DM).

[0317] In some embodiments, the pharmaceutical composition containing CT-388 is administered as an adjunct to another antidiabetic treatment (e.g., metformin treatment) to an overweight or obese patient with T2DM (with or without comorbidities).

[0318] In some embodiments, the pharmaceutical composition containing CT-388 is administered instead of bariatric surgery to an overweight or obese patient with or without T2DM (with or without comorbidities).

[0319] In some embodiments, CT-388 may be administered in combination with one or more other therapeutic agents. Representative other therapeutic agents include, but are not limited to, anti-obesity agents, therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, antihypertensive agents, diuretics, chemotherapeutic agents, immunotherapeutic agents, anti-inflammatory drugs, antithrombotic agents, antioxidants, therapeutic agents for osteoporosis, vitamins, antidementia drugs, erectile dysfunction drugs, therapeutic agents for urinary frequency or incontinence, therapeutic agents for NAFLD, and therapeutic agents for dysuria. In some embodiments, CT-388 may be administered in combination with therapeutic agents that preserve muscle mass.

[0320] IV. Treatment Outcomes

[0321] In some embodiments, patients treated with CT-388 experienced weight loss. For example, patients may experience a placebo-adjusted weight loss of 3 kg or more (e.g., 3.7 kg or more, 4 kg or more, 5 kg or more, 6.0 kg or more, 7.0 kg or more, or 7.4 kg or more). In some embodiments, obese patients experience a weight loss of 7.0 kg or more (e.g., 7.7 kg or more). Patients may also experience a weight loss of 5% or more of their initial body weight (e.g., 9.3% or more, 9.6% or more, 10% or more, 10.2% or more, 10.4% or more, 10.9% or more, 11.5% or more, 11.8% or more, 12.2% or more, 12.4% or more, 12.6% or more, 13% or more, 13.10% or more, 15% or more, 18.3% or more, 18.8% or more, 18.9% or more, or 20%).

[0322] In some embodiments, patients treated with CT-388 experience a reduction in waist circumference. For example, patients may experience a reduction in waist circumference of 7 cm or more (e.g., 9 cm or more, 10 cm or more, or 13.4 cm or more).

[0323] In some embodiments, CT-388 treatment reduces patients' fasting blood glucose, fasting insulin, fasting C-peptide, and / or HOMA-IR. For example, fasting glucose may be reduced by about 4 mg / dL or more (e.g., 5 mg / dL or more, 6 mg / dL or more, 7 mg / dL or more, 8 mg / dL or more, 9 mg / dL or more, 10 mg / dL or more, 11 mg / dL or more, 12 mg / dL or more, 13 mg / dL or more, 14 mg / dL or more, or 15 mg / dL or more). Fasting insulin may be reduced by 1 mIU / L or more (e.g., 2 mIU / L or more, 3 mIU / L or more, or 4 mIU / L or more). Fasting C-peptide may be reduced by 0.2 ng / mL or more (e.g., 0.3 ng / mL or more, 0.4 ng / mL or more, 0.5 ng / mL or more, 0.6 ng / mL or more, 0.7 ng / mL or more, 0.8 ng / mL or more, or 0.9 ng / mL or more). HOM-IR may be reduced by 0.4 or more (e.g., 0.46 or more, 0.5 or more, 0.6 or more, 0.7 or more, 0.8 or more, 0.9 or more, or 1 or more).

[0324] Treatment may also reduce the placebo-adjusted AUC0-120 min of glucose, insulin, or C-peptide in patients. In some embodiments, the AUC0-120 min of glucose decreases by 60 mg*h / dL or more (e.g., 66 mg*h / dL or more, 70 mg*h / dL or more, 80 mg*h / dL or more, 88 mg*h / dL or more, 90 mg*h / dL or more, or 97 mg*h / dL or more). In some embodiments, the AUC0-120 min of insulin decreases by 5 mIU*h / L or more (e.g., 10 mIU*h / L or more, 20 mIU*h / L or more, 30 mIU*h / L or more, 40 mIU*h / L or more, 50 mIU*h / L or more, 60 mIU*h / L or more, or 70 mIU*h / L).(71 mIU*h / L or more, 80 mIU*h / L or more, 90 mIU*h / L or more, 100 mIU*h / L or more, 110 mIU*h / L or more, 120 mIU*h / L or more, or 127 mIU*h / L or more). C-peptide may be reduced by 0.6 ng*h / mL or more (e.g., 0.7 ng*h / mL or more, 1.0 ng*h / mL or more, 2.0 ng*h / mL or more, 3.0 ng*h / mL or more, 4.0 ng*h / mL or more, 5.0 ng*h / mL or more, or 5.1 ng*h / mL or more).

[0325] In some embodiments, treatment reduces peak glucose variability (Cmax) by 10% or more (e.g., 15% or more, 16% or more, 20% or more, 25% or more, 30% or more, or 31% or more) compared to placebo. In some embodiments, treatment reduces insulin Cmax by 20% or more (e.g., 35% or more, 40% or more, 45% or more, 50% or more, or 55% or more). In some embodiments, C-peptide levels are reduced by 15% or more (e.g., 17% or more, 20% or more, 25% or more, 30% or more, 35% or more, or 39% or more).

[0326] Treatment can reduce HOMA-IR to about 1 to about 3 (e.g., to 1.15, 1.75, or 2.37). In some embodiments, patients treated with CT-388 have a reduction in HbA1c of -0.03 or -0.04.

[0327] Treatment may normalize a patient’s glucose metabolism or improve a patient’s insulin sensitivity. Prediabetic patients undergoing CT-388 treatment may have normal blood glucose levels.

[0328] In some embodiments, the CT-388 therapy described herein causes improvement in one or more of the following parameters: weight and metabolic (e.g., blood glucose), including but not limited to weight, fasting blood glucose, fasting insulin, HOMA-IR, waist and hip circumference, fructosamine, HbA1c, fasting lipid profile, fasting free fatty acids, ketone bodies, adiponectin, MRI-PDFF, and biomarkers (ALT, PRO-C3, CK18, and FIB-4).

[0329] V. Articles and formulations

[0330] This disclosure provides articles (e.g., kits) for use in the therapies of this disclosure. The article may contain one or more doses of CT-388. The CT-388 dose may be contained in a pre-filled syringe or syringe, optionally in a disposable syringe or syringe. The article may also include instructions for use.

[0331] In some embodiments, CT-388 is provided as a pharmaceutical composition. The pharmaceutical composition may contain CT-388 at a concentration of 20 mg / mL and may also contain, optionally, sodium phosphate buffer or mannitol at pH 7.0. In some embodiments, the pharmaceutical composition contains CT-388 at a concentration of 20 mg / mL, sodium phosphate buffer, and mannitol (pH 7.0).

[0332] The pharmaceutical composition may contain the components listed in Table 2.

[0333] Table 2. CT-388 Hydrochloride Pharmaceutical Composition Instructions for Use 18 / 65 pages 21 CN 121398835 A

[0334]

[0335] In some embodiments, the pharmaceutical composition is provided in a vial (e.g., a 5 mL glass vial). The vial may be a 20 mm glass vial with a single-hole lyophilized stopper, sealed with a 20 mm flip-top TruEdge matte white sealing gasket. In some embodiments, each vial contains 1.0 mL of the pharmaceutical composition. In some embodiments, each vial contains 20 mg of CT-388.

[0336] VI. Exemplary Embodiments

[0337] Non-limiting exemplary embodiments are provided below to further illustrate this disclosure.

[0338] 1. A compound or a pharmaceutically acceptable salt or ester thereof for use in

[0339] managing weight,

[0340] improving glycemic control and / or

[0341] increasing insulin sensitivity

[0342] in overweight or obese adult patients in need of this, wherein the compound is a compound of Formula I or a compound of Formula II:

[0343]

[0344] (Formula I) [SEQ ID NO:1]

[0345] or specification 19 / 65 pages 22 CN 121398835 A

[0346]

[0347] (Formula II) [SEQ ID NO:1],

[0348] wherein the compound is to be administered subcutaneously at a weight-independent dose of 2.0 mg to about 25 mg.

[0349] 2. The compound or a pharmaceutically acceptable salt thereof used according to Example 1, wherein the patient has a BMI of ≥25 kg / m2, ≥27 kg / m2, ≥30 kg / m2, ≥35 kg / m2, or ≥40 kg / m2.

[0350] 3. The compound or a pharmaceutically acceptable salt thereof used according to Example 1, wherein the patient is obese.

[0351] 4. The compound or a pharmaceutically acceptable salt thereof used according to Example 3, wherein the patient does not have type 2 diabetes or is in the prediabetes stage.

[0352] 5. The compound or a pharmaceutically acceptable salt thereof used according to Example 3, wherein the patient has type 2 diabetes.

[0353] 6. The compound or a pharmaceutically acceptable salt thereof used according to any one of Examples 1 to 5, wherein the patient has one or more weight-related comorbidities, optionally prediabetes, hypertension, or dyslipidemia.

[0354] 7. The compound or a pharmaceutically acceptable salt thereof used according to any one of Examples 1 to 6, wherein the administration steps are repeated weekly, every two weeks, every four weeks, or monthly.

[0355] 8. The compound or a pharmaceutically acceptable salt thereof used according to any one of the foregoing examples, wherein the dose is about 5, 6, 7.5, 8, 12, 16, 17, 22, or 24 mg.

[0356] 9. The compound or a pharmaceutically acceptable salt thereof used according to any one of the foregoing examples, wherein the dose is increased over a period of 3 to 30 weeks.

[0357] 10. The compound or a pharmaceutically acceptable salt thereof used according to Example 9, wherein the starting dose for the increase is about 5 mg or about 8 mg.

[0358] 11. The compound or a pharmaceutically acceptable salt thereof used according to Example 10, wherein the maximum dose for upregulation is about 22 mg or 24 mg.

[0359] 12. The compound or a pharmaceutically acceptable salt thereof used according to any of the preceding examples, wherein the patient receives additional therapy for overweight or obesity, optionally wherein the additional therapy is diet therapy or exercise therapy.

[0360] 13. The compound or a pharmaceutically acceptable salt thereof used according to any of the preceding examples, wherein administration of the compound causes a decrease in the patient's visceral fat and / or HbA1c levels.

[0361] 14. An article comprising the compound or a pharmaceutically acceptable salt thereof used according to any of Examples 1 to 13, wherein the article comprises one or more units of the dose described.

[0362] 15. The article according to Example 14, wherein the article comprises a syringe or syringe, optionally a disposable syringe or syringe.

[0363] 16. A compound or a pharmaceutically acceptable salt or ester thereof for use in treating obesity in adult patients for which such use is desired, wherein the compound is a compound of formula I or a compound of formula II: Specification 20 / 65 pages 23 CN 121398835 A

[0364]

[0365] (Formula I) [SEQ ID NO:1]

[0366] or

[0367]

[0368] (Formula II) [SEQ ID NO:1],

[0369] wherein the compound is to be administered subcutaneously at a weight-independent dose of 2.0 mg to about 25 mg.

[0370] 17. A compound or a pharmaceutically acceptable salt or ester thereof for use in treating type 2 diabetes in adult patients for which such treatment is desired, wherein the compound is a compound of formula I or formula II:

[0371]

[0372] (Formula I) [SEQ ID NO:1]

[0373] or

[0374]

[0375] (Formula II) [SEQ ID NO:1], specification 21 / 65 pages 24 CN 121398835 A

[0376] wherein the compound is to be administered subcutaneously at a weight-independent dose of 2.0 mg to about 25 mg.

[0377] 18. The compound or a pharmaceutically acceptable salt or ester thereof used according to Example 17, wherein the patient is overweight or obese.

[0378] 19. A compound or a pharmaceutically acceptable salt or ester thereof for use in treating obesity or type 2 diabetes in adult patients for which such use is desired, wherein the compound is a compound of formula I or a compound of formula II:

[0379]

[0380] (Formula I) [SEQ ID NO:1]

[0381] or

[0382]

[0383] (Formula II) [SEQ ID NO:1],

[0384] wherein the compound is to be administered subcutaneously at a weight-independent dose of 2.0 mg to about 25 mg.

[0385] Unless otherwise defined herein, scientific and technical terms relating to this invention shall have the meanings commonly understood by one of ordinary skill in the art. Exemplary methods and materials are described below, although similar or equivalent methods and materials may also be used in practice or testing of this disclosure. In case of conflict, this specification (including definitions) shall prevail. Furthermore, unless the context otherwise requires, singular terms shall include plural terms, and plural terms shall include singular terms. Throughout this specification and embodiments, the words “have” and “comprise”, or variations such as “has / having” or “comprises / comprising”, should be understood to imply inclusion of the stated integers or groups of integers, but not to exclude any other integers or groups of integers. All publications and other references mentioned herein are incorporated in their entirety by reference, as if each individual reference were specifically and individually indicated to be incorporated in its entirety by reference. Although numerous references are cited herein, such citations do not constitute an admission that any of these references constitutes part of common general knowledge in the art. As used herein, the terms “about” or “approximately,” when applied to one or more intended values, refer to a value similar to the stated reference value. In some embodiments, the term refers to falling in either direction (greater than or less than) of the stated reference value.The range of values ​​is 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, unless otherwise stated or otherwise apparent from the context.

[0386] According to this disclosure, reverse references in dependent claims are intended to directly and explicitly disclose the abbreviation of each combination of claims indicated by the reverse reference. Any compound disclosed herein may be used in any treatment method herein, wherein the individual to be treated is as defined anywhere herein. Further, the headers herein are created for ease of organization and are not intended to limit the scope of the claimed invention in any way.

[0387] The following examples are set forth in order to better understand the invention. These examples are for illustrative purposes only and should not be construed as limiting the scope of this disclosure in any way.

[0388] Examples

[0389] Example 1: Phase 1 Clinical Trial Protocol

[0390] This example outlines the protocol for a Phase 1 randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of CT-388 in otherwise healthy overweight and obese adult participants and obese patients with type 2 diabetes.

[0391] For once-weekly administration, 1 mL or 2 mL of lyophilized powder or sterile solution of CT-388 at a concentration of 20 mg / mL, or placebo, was provided as a sterile solution for subcutaneous (SC) injection.

[0392] A. Objectives

[0393] Single-Dose Escalation (SAD) Once-Weekly (QW)

[0394] The primary objective of this study was to determine the safety and tolerability of CT-388 administered as a single dose of 0.5, 2.0, 5.0, 6.0, or 7.5 mg in otherwise healthy overweight and obese adult participants.

[0395] Secondary objectives were:

[0396] • to evaluate the pharmacokinetics of a single escalation dose of CT-388 in otherwise healthy overweight and obese adult subjects; and

[0397] • to evaluate the pharmacodynamic (PD) effects of a single dose of CT-388 on body weight and glucose homeostasis in otherwise healthy overweight and obese adult participants in a fasting state and a mixed diet tolerance test (MMTT) challenge.

[0398] Multiple Escalation Dose (MAD) QW

[0399] The primary objective of this study was to determine the safety and tolerability of CT-388 administered weekly at a titrated dose for 4 consecutive weeks in otherwise healthy overweight and obese adult participants.

[0400] Secondary objectives of this study were:

[0401] • to evaluate the pharmacokinetics of CT-388 at a weekly titrated dose for 4 consecutive weeks; and

[0402] • to evaluate the effects of a weekly titrated dose of CT-388 for 4 consecutive weeks.The PD effects on body weight and glucose homeostasis in otherwise healthy overweight and obese participants in fasting and oral glucose tolerance test (OGTT) settings.

[0403] Multiple dose (MD) QW

[0404] The primary objective of this study was to determine the safety and tolerability of CT-388 administered weekly at a titrated dose for 12 consecutive weeks (for cohorts 11 and 14) in participants with and without type 2 diabetes mellitus (T2DM) (for cohorts 12 and 13, the duration was up to 24 weeks).

[0405] The secondary objectives of this study were:

[0406] • to evaluate the pharmacokinetics of CT-388 administered for 12 consecutive weeks (for cohorts 11 and 14) (for cohorts 12 and 13, the duration was up to 24 weeks); and

[0407] • to evaluate the PD effects of CT-388 administered for 12 consecutive weeks (for cohorts 11 and 14) on body weight and glucose homeostasis in participants with or without T2DM in fasting and OGTT settings (for cohorts 12 and 13, the duration was up to 24 weeks).

[0408] The exploratory objectives of this study are:

[0409] • to evaluate the effects of CT-388 dose titration for 12 consecutive weeks and additionally for up to 24 weeks on PD in participants without T2DM (cohort 12) or with T2DM (cohort 13); and

[0410] • to evaluate the effects of CT-388 dose titration for 12 consecutive weeks in cohorts 11 to 14 on biomarkers (e.g., lipid profile, adiponectin, alanine aminotransferase (ALT), Pro-C3, CK18, FIB-4) and additionally for up to 24 weeks in participants without T2DM (cohort 12) or with T2DM (cohort 13).

[0411] B. Endpoints

[0412] Safety and tolerability will be assessed by monitoring adverse events (AEs), measuring vital signs and ECG, and performing clinical laboratory blood and urine analyses.

[0413] C. Pharmacodynamics

[0414] PD assessment includes weight from baseline to the predetermined date, fasting blood glucose, fasting insulin, HOMA-IR, waist and hip circumference, fructosamine, HbA1c, fasting lipid profile, fasting free fatty acids, ketone bodies, adiponectin, MRI-PDFF, biomarkers (ALT, PRO-C3, CK18, and FIB-4), and AUC, baseline-adjusted AUC, Cmax, and Tmax.Changes.

[0415] D. Main Inclusion Criteria

[0416] Cohorts 1 to 6 will include overweight or obese adult male or female participants aged 18 to 65 years (inclusive) with a body mass index (BMI) ≥25.0 kg / m2 (inclusive) and otherwise healthy.

[0417] Cohorts 7 to 12 and 14 will include overweight or obese adult male or female participants aged 18 to 65 years (inclusive) with a BMI ≥30.0 ​​kg / m2 (inclusive) and otherwise healthy. Abnormal blood pressure (i.e., treated hypertension), blood lipids (i.e., treated hyperlipidemia), and blood glucose levels consistent with a diagnosis of prediabetes are acceptable.

[0418] Cohort 13 will include adult male or female participants aged 18 to 65 years (inclusive) with a BMI ≥30.0 ​​kg / m2 (inclusive), diagnosed with T2DM ≥6 months and managed solely by diet and exercise, or having received at least a stable dose of metformin monotherapy for at least 3 months prior to the screening visit, and with HbA1c between 7.0% and 10.0%. Other abnormalities in blood glucose, blood lipids, urine glucose, and urine protein consistent with the diagnosis of T2DM are acceptable.

[0419] E. Inclusion Criteria

[0420] The inclusion criteria for participants in all cohorts include the following:

[0421] 1) Male or female, aged between 18 and 65 years (inclusive) at the time of consent.

[0422] 2) Female participants must not be pregnant or breastfeeding.

[0423] 3) Cohorts 1 to 6 had a BMI ≥ 25.0 kg / m2 (inclusive) at screening and admission (day -2 / day -1); Cohorts 7 to 14 had a BMI ≥ 30.0 kg / m2 (inclusive) at screening and admission (day 2 / day -1).

[0424] 4) Two months prior to screening, based on participants' verbal reports and between screening and admission (day -2 / day -1), their weight was stable (defined as a weight gain or loss ≤ 4.0 kg) based on measured weight.

[0425] 5) At screening and admission (day -2 / day -1), the principal investigator (PI) or representative considered, based on medical history, physical examination, vital signs, and laboratory test results, that there were no clinically significant symptoms, signs, or stable active manifestations of the disease.

[0426] F. Exclusion Criteria

[0427] Exclusion criteria for participants in all cohorts included the following:

[0428] 1) A clinically significant history or active clinical manifestation of any major metabolic, allergic, skin, liver, kidney, blood, lung, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (such as PI).(or as determined by the representative). However, based on the judgment and decision of the Investigator’s Statement, pages 24 / 65, 27 CN 121398835 A or the representative, the following exceptions may be considered:

[0429] a) Participants with non-severe gastroesophageal reflux disease may be permitted if they have remained stable for >3 months prior to screening on proton pump inhibitor therapy.

[0430] b) Participants with stable asthma (i.e., no exacerbation or use of asthma relievers in the 3 months prior to screening) and who are expected to be stably managed during the study.

[0431] c) Participants with stable depression who have been treated with a stable dose and regimen of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) for more than 12 months prior to screening may be permitted; however, participants with a history of depression requiring hospitalization / ECT / previous treatment with antipsychotic medication and / or requiring ongoing psychotherapy and / or treatment with any central nervous system stimulant (e.g., Ritalin-SR® for ADHD) are excluded.

[0432] d) Participants may be taking medications to control high blood pressure (e.g., ACE inhibitors) or high cholesterol (e.g., statins / fibrates), provided that their blood pressure and lipid parameters are under stable control, and that the dosage and regimen have been stable for more than 3 months prior to the screening visit, and that the medication / dosage / regimen is not expected to change during the study.

[0433] 2) A current diagnosis of any type of diabetes (as defined in the 2022 American Diabetes Association Standards of Diabetes (Clin Diabetes (2022) 40(1):10–38), except for cohort 13 which requires a diagnosis of T2DM)

[0434] a) Participants with prediabetes (as defined in the 2022 American Diabetes Association Standards of Diabetes (Clin Diabetes (2022) 40(1):10–38)) may be allowed, provided that they control and maintain their diabetes solely through diet / exercise (i.e., no type of pharmacological treatment is permitted, including no metformin, and no other type of over-the-counter medication / herbal / over-the-counter / complementary treatment is permitted).

[0435] 3) History of bariatric surgery (any type) or gastric banding (including LAP-BAND), any gastrointestinal surgery that may induce malabsorption (e.g., bowel resection) or any GI motility disorder, gastroparesis, delayed gastric emptying, inflammatory bowel disease, pancreatitis, malabsorption syndrome, chronic diarrhea, chronic constipation, or clinically significant irritable bowel syndrome.

[0436] 4) Screening, admission (day 2 / day 1), and day 1 (before administration) with semi-supine systolic blood pressure > 160 mm Hg and / or diastolic blood pressure > 95 mm Hg.

[0437] 5) Active or untreated malignant tumors, or remission for less than 5 years from clinically significant malignant tumors (excluding basal cell or squamous cell skin cancer, cervical cancer in situ or prostate cancer in situ) prior to screening. Personal or family history of medullary thyroid carcinoma (MTC) (first-degree relatives), or a genetic predisposition to MTC (i.e., thyroid C-cell hyperplasia or multiple endocrine neoplasia type 2A or 2B)

[0438] 6) History of atopic (severe or multiple allergic manifestations) or clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post-treatment hypersensitivity; known allergy to any component of the drug composition, GLP-1 analogues, or related compounds

[0439] 7) Any of the following laboratory abnormalities at screening visit (some exceptions to this criterion apply to cohort 13 requiring a diagnosis of T2DM; see below):

[0440] a) Aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT] >2 × upper limit of normal (ULN), or

[0441] b) Total bilirubin > ULN

[0442] c) Amylase and lipase > ULN

[0443] d) Fasting triglycerides ≥ 250 mg / dL (2.83 mmol / L) Instructions for use 25 / 65 pages 28 CN 121398835 A

[0444] e) Estimated glomerular filtration rate (eGFR) < 60 mL / min / 1.73 m2 calculated by the central laboratory using the Chronic Kidney Disease Epidemiological Collaborative Study (CKD-EPI) formula at the time of screening.

[0445] f) HbA1c level ≥ 6.5%

[0446] g) Fasting blood glucose ≥ 126 mg / dL (6.9 mmol / L)

[0447] h) Hemoglobin < 11 g / dL (male) or < 10 g / dL (female)

[0448] 8) Currently using or using any prescription or over-the-counter medications known to interfere with bowel motility within 3 months prior to screening, including but not limited to chronic opioids, anticholinergics, and antispasmodics.

[0449] 9) Using hormone replacement therapy (excluding oral contraceptives / intrauterine devices / intrauterine devices) for 60 days prior to admission (day-2 / day-1).

[0450] For eligibility to enroll in cohort 13 (multiple-dose administration for 24 weeks in obese participants with T2DM), all of the above inclusion and exclusion criteria should be met, including the following additional criteria:

[0451] 1) Diagnosis of diabetes as defined in the 2022 American Diabetes Association Standards of Clinical Diabetes (Clin Diabetes) at least 6 months prior to the screening visit.(2022) 40(1):10–38) as defined T2DM,

[0452] 2) T2DM should be managed with diet and / or exercise alone for at least 3 months prior to the screening visit, or with a stable dose of metformin monotherapy (immediate or extended release ≥500 mg / day and not exceeding the locally approved dose).

[0453] 3) BMI ≥ 30.0 kg / m2,

[0454] 4) HbA1c between 7.0% and 10.0% (inclusive),

[0455] 5) At screening, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase (GGT) are allowed to be up to 3× the upper limit of the normal (ULN) range and total bilirubin is allowed to be up to 1.5× ULN; other abnormalities in serum (e.g., glucose, lipids) and urine (e.g., glucose, protein) consistent with the diagnosis of T2DM are acceptable,

[0456] 6) At screening, fasting serum triglyceride levels are allowed to be up to 500 mg / dL (5.6 mmol / L),

[0457] 7) At screening, eGFR calculated by the central laboratory using the CKD-EPI formula should be > 45 mL / min / 1.73 m2,

[0458] 8) Fasting blood glucose should be < 270 mg / dL (14.8 mmol / L) during screening.

[0459] G. Test Product, Dosage, and Administration

[0460] Participants will receive one of the following treatments:

[0461] SAD QW – Cohorts 1 to 5

[0462] ● Cohort 1: Subcutaneous administration of a dose containing 0.5 mg CT-388 or a matched placebo in the abdomen

[0463] ● Cohort 2: Subcutaneous administration of a dose containing 2.0 mg CT-388 or a matched placebo in the abdomen

[0464] ● Cohort 3: Subcutaneous administration of a dose containing 5.0 mg CT-388 or a matched placebo in the abdomen

[0465] ● Cohort 4: Subcutaneous administration of a dose containing 7.5 mg CT-388 or a matched placebo in the abdomen

[0466] ● Cohort 5: Subcutaneous administration of a dose containing 6.0 mg CT-388 or a matched placebo in the abdomen

[0467] MAD QW – Cohorts 6 to 10

[0468] ● Cohort 6: Weekly titration for 4 consecutive weeks, CT-388 dose as follows…

[0469] • Day 1, 5.0 mg

[0470] • Day 8, 5.0 mg

[0471] • Day 15, 5.0 mg

[0472] • Day 22, 7.5 mg

[0473] …or subcutaneous administration of a matched placebo in the abdomen. (Instructions for Use, pages 26 / 65, 29 CN 121398835 A)

[0474] ● Cohort 7: Weekly titration for 4 weeks, CT-388 dose was…

[0475] • Day 1, 5.0 mg

[0476] • Day 8, 5.0 mg

[0477] • Day 15, 8.0 mg

[0478] • Day 22, 12.0 mg

[0479] …or subcutaneous administration of a matched placebo in the abdomen

[0480] ● Cohort 8: Weekly titration for 4 weeks, CT-388 dose was…

[0481] • Day 1, 5.0 mg

[0482] • Day 8, 8.0 mg

[0483] • Day 15, 12.0 mg

[0484] • Day 22, 12.0 mg

[0485] …or subcutaneous administration of a matched placebo in the abdomen (based on tolerability data from Cohort 7, the third dose in Cohort 8 could be reduced to 8.0 mg)

[0486] ● Cohort 9: Weekly titration for 4 consecutive weeks, CT-388 dose as follows:

[0487] • Day 1, 8.0 mg

[0488] • Day 8, 8.0 mg

[0489] • Day 15, 12.0 mg

[0490] • Day 22, 16.0 mg

[0491] ……or subcutaneous administration of a matched placebo in the abdomen

[0492] ● Cohort 10: The following two dosing options are presented in Table 3 below:

[0493] Table 3. Cohort 10 Options

[0494]

[0495] MD QW – Cohorts 11 to 14

[0496] The primary purpose of these cohorts is to enable longer titration protocols to better characterize tolerability curves so that each participant can reach their respective maximum tolerated dose. In cohorts 12 and 13, participants will also have the opportunity to continue taking this dose for an additional 12 weeks (i.e., a total of 24 weeks of dosing) to better assess the safety and tolerability of the study drug over a longer period.

[0497] Generally, when titrating up the dose, if the dose is not tolerated at any stage, the dose is restored to the previously tolerated dose at the next dose (i.e., down-adjustment is permitted), and then an up-adjustment is attempted at subsequent scheduled dosing times / weeks.

[0498] For all MD QW cohorts, the following should be done to achieve a smooth up-adjustment of the dose:

[0499] ● Tailor a flexible and individualized titration plan based on the participant’s specific level of tolerance,

[0500] ● Temporarily discontinue the study drug, and / or the package insert 27 / 65 pages 30 CN 121398835 A

[0501] ● Enhance conservative measures (i.e., reduce the amount of food per meal, reduce the frequency of meals / skip meals) and according to clinicalIndications for the use of appropriate concomitant medications to manage associated adverse events (AEs).

[0502] The cohorts in the MD QW study are as follows.

[0503] ● Cohort 11: Administered once weekly via SC to the abdomen for 12 consecutive weeks, with CT-388 or a matched placebo administered at a dose of 5.0 mg for the first 3 weeks, followed by titration to 8.0 mg over the duration of treatment. If a participant experienced moderate to severe tolerability issues after the third 5 mg dose, the same 5 mg dose could be continued for up to 2 additional weeks, i.e., titration to 8 mg could be attempted after the fourth or fifth 5 mg dose. If a participant was still unable to tolerate 8 mg by day 36, the participant could continue taking 5 mg for the remainder of the treatment duration.

[0504] ● Cohorts 12 and 13: CT-388 was administered once weekly via SC to the abdomen for 12 consecutive weeks, with the following doses of CT-388 or a matched placebo:

[0505] • Day 1 and Day 8, 5.0 mg

[0506] • Day 15 and Day 22, 8.0 mg

[0507] • Day 29 and Day 36, 12.0 mg (or 8.0 mg based on tolerability)

[0508] • Day 43 and Day 50, 17.0 mg (or 12.0 mg based on tolerability)

[0509] • Day 57, 22.0 mg (or 12.0 mg or 17.0 mg based on tolerability).

[0510] If the dose on Day 57 was 22 mg, that dose was continued for the duration of treatment.

[0511] If the dose on day 57 is 12 mg or 17 mg, titration to the next higher dose level may be attempted weekly based on individual tolerability (e.g., if a 12 mg dose is administered on day 57 and tolerated, a 17 mg dose may be attempted on day 64).

[0512] If not tolerated, continue at the previously tolerated dose level until the next week (e.g., until day 71), at which point the next higher dose level may be attempted again.

[0513] The next higher dose level may be attempted until day 78.

[0514] The dose level reached on day 78 should be administered once weekly for an additional 12 weeks during the extension period, bringing the total cumulative dose for participants in cohorts 12 and 13 to 24 weeks. At any time during the extension period, if maintenance dose is not tolerated, the dose may be reduced by a corresponding dose level (e.g., if the dose is 22 mg, reduced to 17 mg; if the dose is 17 mg, reduced to 12 mg), and / or administration may be paused for up to 2 weeks. During the temporary dose adjustment / After the pause, titration back to the previous (higher) dose level should be attempted. If poor tolerability still occurs, or if the investigator believes that a participant may discontinue the study due to poor tolerability, the previously tolerated dose (provided it is at least 12 mg) may be continued for the remainder of the extension period.

[0515] ● Dosing in Cohort 14 may follow one of the two dosing options shown in Table 4 below.

[0516] Table 4. Cohort 14 Option Instructions 28 / 65 pages 31 CN 121398835 A

[0517]

[0518] Example 2: Safety and Efficacy Data of CT-388 Treatment for Four Weeks

[0519] The data described in this example show that CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, was safe and well-tolerated in overweight and obese adults in a clinical study conducted according to the protocol described in Example 1, and produced more than 8% weight loss over 4 weeks.

[0520] A. Methods

[0521] A phase 1, randomized, placebo-controlled, double-blind study was conducted in which single escalation dose (SAD; n = 40; 0.5 to 7.5 mg) and multiple escalation dose (MAD; n = 24; 5 to 12 mg via titration in 3 cohorts) were administered to overweight / obese adults as described in Example 1.

[0522] The primary objective of this study was to investigate the safety and tolerability of CT-388 in overweight or obese but otherwise healthy adult participants. The secondary objective of this study was to determine the pharmacokinetic (PK) characteristics of CT-388 and to investigate the effects of CT-388 on pharmacodynamic (PD) parameters of obesity, such as weight, glycemic control, glucose homeostasis, and insulin sensitivity. A total of 64 participants (male / female: 28 / 36; median age / BMI: 34 years / 33 kg / m2; 40 patients in the SAD arm and 24 patients in the MAD arm) received at least one dose of CT-388 or placebo.

[0523] The 24 patients in the MAD arm were divided into three cohorts (cohorts 6, 7, and 8) as shown in Table 5 below (EOT: end of treatment).

[0524] Table 5. MAD Dosing Regimen

[0525]

[0526] Briefly, participants were randomized in a 3:1 ratio (6 received CT-388 and 2 received placebo, n = 8 per cohort). In all cohorts, CT-388 was administered once weekly at a dose of 5 mg at baseline, up to 12 mg in cohorts 7 and 8. At baseline (-1On day 20) and day 23, an oral glucose tolerance test (OGTT) was performed using a 75 g glucose solution. Blood samples were collected 15 min before the OGTT, at the start of the OGTT, and at 30-minute intervals up to 120 minutes. Fasting blood glucose, insulin, C-peptide, and HOMA-IR were measured / calculated at baseline and day 23.

[0527] The demographic and baseline characteristics of the MAD participants enrolled in this study are shown in Table 6 below.

[0528] Table 6. MAD Demographic and Baseline Characteristics 30 / 65 pages 33 CN 121398835 A

[0529]

[0530] * Mean (SD) value (in parentheses); ** Median (in parentheses)

[0531] B. Results

[0532] PK characteristics were studied over a wide dose range (0.5 to 12 mg) and supported once-weekly administration. On day 29, in the three MAD cohorts, participants treated with CT-388 were dose-responsive to changes in percentage of body weight relative to baseline compared with placebo (p < 0.0001), with placebo-adjusted least-squares mean differences [95% CI] of -4.8% [-6.3, -3.3], -6.4% [-7.8, -5.0], and -8.5% [-10.4, -6.7]. In the cohort receiving up to 12 mg of CT-388, mean percentage reductions in fasting blood glucose (↓8% to 10%), insulin (↓20% to 26%), HOMA-IR (↓26% to 33%), AUC0-120 min glucose (↓26% to 28%), and AUC0-120 min insulin (↓33% to 58%) from baseline were observed on day 23 during the oral glucose tolerance test (OGTT), suggesting improved insulin sensitivity. CT-388 was generally well tolerated during the 4-week treatment period, with no serious adverse events or treatment-related discontinuations in the MAD cohort. The most common reported side effects were gastrointestinal (decreased appetite, nausea, vomiting, diarrhea), most of which were mild in severity. These data are discussed in detail below.

[0533] B.1. Summary of SAD Cohorts 1 to 5

[0534] Safety Assessment

[0535] Preliminary and blinded safety and tolerability data indicate that CT-388 was generally well tolerable, with most treatment-interventional adverse events (TEAEs) related to GI, consistent with the expected AE characteristics of insulin-based (GLP-1R agonists and dual GLP-1R / GIPR agonists) drug classes, as shown in Tables 7A and 7B below.

[0536] Table 7A. AEs in the SAD CohortFrequency / Type Specification 31 / 65 pages 34 CN 121398835 A

[0537]

[0538] Table 7B. Specific AEs and verbatim terminology reported for the SAD cohort Specification 32 / 65 pages 35 CN 121398835 A

[0539]

[0540] Most of these AEs are considered mild. In cohorts 1 to 3, clinically significant AEs were generally not reported, nor were changes in vital signs, ECG, physical examination or laboratory test results reported.

[0541] Pharmacokinetics

[0542] The time-concentration curves after a single dose of CT-388 administered to participants in cohorts 1 (0.5 mg), 2 (2 mg), 3 (5 mg), 4 (7.5 mg) and 5 (6 mg) are shown in Table 8 below.

[0543] Table 8. PK Parameters from the SAD Cohort, Page 33 / 65, CN 121398835 A

[0544]

[0545] * CL / F: Oral clearance; MRTlast: Mean residence time from dosing time to the last measurable concentration; t1 / 2: Half-life (shown as a range from minimum to maximum); Vz / F: Volume of distribution. All values ​​are mean ± standard deviation.

[0546] With increasing dose, Cmax and AUC0-t were observed to increase substantially proportionally, except in Cohort 5, which appeared to be less than dose-proportional (Figures 1A and 1B). Samples from Cohort 5 were reanalyzed to validate initial results similar to those initially observed. Tmax occurred after 24 hours in all but two individual cases. t1 / 2 (median approximately 120 hours) was consistent with the once-weekly dosing regimen of CT-388. Figure 1C summarizes the preliminary PK parameters for each cohort 1 to 5.

[0547] B.2. Summary of MAD cohorts 6 to 8

[0548] Safety assessment

[0549] The TEAEs associated with CT-388 administration in the MAD study are summarized in Table 9 below.

[0550] Table 9. TEAEs in the MAD cohorts Instructions for use 34 / 65 pages 37 CN 121398835 A

[0551]

[0552] Gastrointestinal (GI) TEAEs are shown in Table 10 below.

[0553] Table 10. GI TEAEs in the MAD cohorts

[0554]

[0555] The severity of gastrointestinal TEAEs is shown in Table 11 below.

[0556] Table 11. GI TEAEs in the MAD cohortsTEAE Severity Instructions 35 / 65 Page 38 CN 121398835 A

[0557]

[0558] * Each subject contributes once to each of the incidence rates.

[0559] ** The same subject experienced both mild and moderate events.

[0560] In summary, CT-388 12 mg was generally well tolerated when administered on a weekly up-regulation schedule over 4 weeks.

[0561] Efficacy

[0562] Weight Loss

[0563] Enrolled patients had a mean body weight (BW) of 94 kg. A robust BW dose response was observed after 4 weeks of CT-388 administration. Clinically and statistically significant weight loss (WL) was produced in all dose arms compared to placebo. Specifically, four weeks after CT-388 administration, the placebo-adjusted (adj) waist circumference (WL) (mean LS) in cohorts 6, 7, and 8 were 3.7 kg, 6.0 kg, and 7.4 kg, respectively (all p < 0.001). The WL effect persisted for up to two weeks after CT-388 discontinuation (Figures 2A and 2B). The effect of CT-388 on waist circumference was observed after the first dose and improved over time. The greatest beneficial effect was observed in obese participants, with WL as high as 7.7 kg (approximately 17 lbs), 8.4%.

[0564] Waist circumference reduction was observed after CT-388 treatment, which was associated with a reduction in visceral fat (Figure 3).

[0565] Glucose and Insulin Response

[0566] On day -1, the fasting blood glucose levels of the OGTT in cohorts 6, 7, and 8 were 94 mg / dL, 99 mg / dL, and 98 mg / dL, respectively; the level in the placebo arm was 95 mg / dL. On day -1, the fasting insulin levels of the OGTT in cohorts 6, 7, and 8 were 10 mIU / L, 19 mIU / L, and 41 mIU / L, respectively; the level in the placebo arm was 12 mIU / L. On day -1, the fasting C-peptide levels of the OGTT in cohort 6 were 2.73 ng / mL, in cohort 7 were 3.55 ng / mL, in cohort 8 were 4.18 ng / mL, and in the placebo group were 12.22 ng / mL. On day -1, the HOMA-IR for cohorts 6, 7, and 8 were 2.2, 4.7, and 13.2, respectively; the HOMA-IR for patients in the placebo arm was 2.8.

[0567] After four CT-388 doses, the placebo-adjusted differences in cohorts 6, 7, and 8 relative to the placebo arm were: fasting blood glucose -13 / -5 / -15mg / dL; fasting insulin: -1 / 2 / -4 mIU / L; fasting C-peptide: -0.2 / 0.5 / -0.9 ng / mL; and HOMA-IR: -0.46 / 0.58 / -1. In cohorts 6, 7, and 8, the placebo-adjusted reductions in AUC0-120 min were 66 mg*h / dL, 97 mg*h / dL, and 88 mg*h / dL for glucose (p<0.001 across all cohorts); 5 mIU*h / L, 127 mIU*h / L, and 71 mIU*h / L for insulin (p<0.5 in cohort 6); and 0.6 ng*h / mL, 0.7 ng*h / mL, and 5.1 ng*h / mL for C-peptide (p<0.05 in cohorts 7 and 8). A decrease in HOMA-IR (insulin sensitivity marker) was observed after CT-388 therapy, suggesting improved insulin sensitivity (Figure 4).

[0568] In summary, on day 23, glucose AUC0-120 min was significantly reduced in all CT-388 cohorts compared to placebo (P<0.001 in all cohorts); and insulin AUC0-120 min and C-peptide AUC0-120 min were lower in participants with a baseline BMI ≥30 kg / m2 (cohorts 7 and 8). See Figures 5 and 6. In all CT-388 cohorts, peak glucose offset (Cmax) was reduced by 16% to 31% compared to placebo (P<0.05), accompanied by reduced Cmax of insulin (20% to 55% in cohorts 7 and 8) and C-peptide (17% to 39% in cohorts 7 and 8). Furthermore, on day 23, improvements in fasting blood glucose were observed in all CT-388 cohorts compared to placebo (P=0.001 in cohorts 6 and 8). On day 23, fasting insulin, C-peptide, and HOMA-IR were also significantly lower in cohort 8 compared to placebo (P<0.05).

[0569] Table 12. HOMA-IR

[0570]

[0571] *Values ​​represent geometric mean; **HOMA-IR on day 23 compared to placebo P=0.02

[0572] Pharmacokinetics (PK)

[0573] The mean (± SD) plasma concentrations (ng / ml) versus time (hours) after CT-388 or placebo administration on day 8 are shown in Figures 7A and 7B. Cmax was observed in each queue.The AUC0-t increased approximately proportionally. PK data were consistent with once-weekly (QW) dosing. Plasma exposure to CT-388 appeared to be lower in participants with higher baseline body weight (BW).

[0574] Conclusion

[0575] CT-388, starting at a dose of 5 mg and escalated to 12 mg over 4 weeks, demonstrated good tolerability in both overweight and obese participants. Tolerability appeared more favorable in obese participants compared to overweight participants. Most common TEAEs were GI-related, consistent with incretin classes, and there was no transient pattern of AEs during dose escalation. PK characteristics supported once-weekly (QW) dosing. CT-388 administration at 5 / 8 / 12 / 12 mg resulted in 8.4% weight loss (7.7 kg, approximately 17 lbs), accompanied by reductions in waist and hip circumference and improvements in insulin sensitivity markers (HOMA-IR). Given the highest weight loss and favorable tolerability, obese patients show significant benefit from CT-388 treatment instructions, pages 37 / 65, 40 CN 121398835 A.

[0576] In summary, CT-388 provides clinically significant weight loss and metabolic control with favorable tolerability. Administration of CT-388 to insulin-resistant overweight or obese patients induces clinically significant weight loss (WL), accompanied by improved insulin sensitivity (HOMA-IR) and glucose homeostasis. These findings suggest that CT-388 may reduce the risk of T2D in obese individuals and has beneficial effects on glucose metabolism and induction of disease remission in patients with T2D. These data make further clinical evaluation of CT-388 in the treatment of obesity, T2DM, and other weight-related comorbidities necessary, possibly with minimal or no titration.

[0577] Example 3: Safety and efficacy data of CT-388 treatment in cohorts 11 and 12

[0578] Trial Design

[0579] CT-388-101 was the first human phase 1, double-blind, placebo-controlled, single-center study. Figure 8 shows the seamless phase 1 / 2 design of the trial. In arm 3, patients with BMI ≥ 30 and without T2D were treated with doses up to 22 mg for up to 24 weeks, while patients with BMI ≥ 30 and with T2D were treated with doses up to 22 mg for up to 12 weeks.

[0580] A total of 129 participants were enrolled in CT-388-101 and received at least one dose of CT-388 or placebo. In the SAD phase (n = 40:3:1 ratio; overweight or obese and without T2D), 0.5 mg to7.5 mg CT-388. In the MAD QW phase (n = 24:3:1 ratio; overweight or obese and without T2D), up to 12 mg CT-388 was administered over four weeks. In the MD QW phase (n = 60; 4:1 ratio; obese with or without T2D), up to 22 mg was administered over 12 to 24 weeks, and 45 non-T2D patients were enrolled.

[0581] Figure 9 illustrates the CT-388-101 MD phase design. Cohorts 11 and 12 included obese participants without T2DM, and cohort 13 included obese patients with T2DM. The endpoints of this study were safety, including TEAE, laboratory findings, vital signs, and ECG; PK, including CT-388 PK concentrations and parameters; and key PD endpoints, including at week 12 (D85) and week 24 (D169):

[0582] a. Weight: % change; absolute change;

[0583] b. Changes in HbA1c, fasting blood glucose, fasting insulin, and HOMA-IR; and

[0584] c. Waist and hip circumference.

[0585] Demographics and Baseline Characteristics

[0586] Most CT-388 patients were female and obese (BMI ≥ 35 kg / m2). Other baseline characteristics were similar between placebo and CT-388 patients (Table 13). Although baseline mean HbA1c and fasting blood glucose were within the normal range, approximately 50% of patients met the ADA definition of prediabetes / diabetes (based on ADA criteria extrapolated post-hoc, only glucose at 120 minutes after OGTT (day -1) reached the diagnostic threshold (>200 mg / dL)). Baseline was defined as the last observation obtained prior to the first dose of the study drug.

[0587] Table 13. CT-388-101 MD Demographics and Baseline Characteristics Specification 38 / 65 pages 41 CN 121398835 A

[0588]

[0589] Figure 10 illustrates subject treatment in the CT-388-101 MD trial. In patients treated with 8 mg, all patients were administered as scheduled. In patients treated with 22 mg, 75% were administered as scheduled and completed the 22 mg treatment, while 25% were downgraded and completed the 12 mg treatment. No patients completed the 17 mg treatment.

[0590] Efficacy information sheet, 39 / 65 pages, 42 CN 121398835 A

[0591] At week 12, both CT-388 8 mg and 22 mg causedRobust, statistically significant, dose-dependent, and clinically significant weight loss. At week 24, CT-388 caused 18.8% placebo-adjusted weight loss, confirming further weight loss with extended treatment (Figure 11, Table 14).

[0592] Table 14. LSM and 95% CI of placebo-adjusted weight loss %

[0593]

[0594] When adjusted for sex and weight at BSL, CT-388 22 mg caused -20.7% placebo-adjusted weight loss at week 24 (Figure 12, Table 15).

[0595] Table 15. LSM and 95% CI of placebo-adjusted weight loss %

[0596]

[0597] CT-388 caused robust and clinically significant weight loss at weeks 12 and 24 of treatment (Figure 13, Table 16). Weight loss began after the first dose of CT-388 and continued to decrease during treatment. No plateau was observed at week 12 (8 mg) or week 24 (22 mg).

[0598] Table 16. Final unblinded assessment of weight loss by treatment group, considering the effect of baseline weight using an MMRM model. (Instructions for Use, Page 40 / 65, 43 CN 121398835 A)

[0599]

[0600] Weight loss was assessed by unblinded treatment group, considering the effect of baseline weight using an MMRM model (Figure 14, Table 17). Observed weight values ​​were measured within 8 days after the last dose of the study drug. Regardless of the final dose, participants who deviated from the planned dose-upgrade path had similar weight loss as those who followed the path. The primary cause of dose-downgrades was tolerance symptoms, which were managed through dose adjustments, enabling patients to complete the study and still lose significant weight.

[0601] Table 17. Final nonblinded assessment of weight loss in cohort 12, considering the effect of baseline weight using the MMRM model, based on the actual final dose.

[0602]

[0603] By week 24, 85% of patients treated with CT-388 22 mg achieved >10% WL, and 45% had WL greater than 20% (Figure 15).

[0604] By week 12, CT-388 8 mg and 22 mg caused significant and clinically meaningful waist circumference reduction of approximately 10 cm (Figure 16, Table 18). With prolonged treatment, CT-388 22 mg caused a further waist circumference reduction of -13.7 cm at week 24. The reduction in waist circumference indicates a reduction in visceral fat and translates to a reduction of approximately 2 to 3 garment sizes.

[0605] Table 18. Placebo-adjusted LSM and 95% CI for changes in waist circumference (cm) Instructions for Use 41 / 65 pages 44 CN 121398835 A

[0606]

[0607] CT-388 8 mg and 22 mg showed a potential beneficial effect on HbA1c, even in participants with normal HbA1c at baseline (<5.7%) (Figures 17A to 17B, Table 19).

[0608] Table 19. PBO-adjusted LSM and 95% CI for changes in HbA1c (%)

[0609]

[0610] Based on three ADA criteria, all CT-388 participants were able to normalize their glucose metabolism (Figure 18, Table 20, Table 21). At baseline, 37.5% of patients assigned to CT-388 22 mg were prediabetic / diabetic. At week 24, none of the participants who completed CT-388 treatment had prediabetes or diabetes. As used herein, normal blood glucose was defined as HbA1c <5.7%, fasting blood glucose <100 mg / dL, and 2-hour post-OGTT blood glucose <140 mg / dL.

[0611] Table 20. Shift of blood glucose status from baseline to week 24 in cohort 12

[0612]

[0613] Table 21. Shift of blood glucose status from baseline to week 24 in cohort 12

[0614]

[0615] Pharmacokinetics

[0616] The corresponding separation in the trough concentration and mean %WL curves at approximately week 8 / 9 indicates a strong exposure-response relationship between CT-388 concentration and WL value. CT-388 PK supports weekly dosing (t1 / 2 is approximately 150 hours) and is consistent with previous PK data from the SAD and MAD cohorts. Pharmacokinetic results continue to support once-weekly dosing of CT-388.

[0617] Safety and Tolerability Data Sheet 42 / 65 pages 45 CN 121398835 A

[0618] CT-388 is generally safe and well-tolerated during treatment up to 24 weeks, with AEs consistent with the insulin drug class, although titration was rapid and steep. No SAEs or GI-related AEs associated with severe treatment were observed in CT-388 participants. Vital signs, ECG, and safety laboratory findings were not clinically significant and followed patterns consistent with the incretin drug class.

[0619] Summary and Conclusion

[0620] The Phase I results for CT-388 in obese patients were positive. This study found that, compared with placebo, at 24 weeksSubcutaneous injections of CT-388 once weekly resulted in significant weight loss in obese healthy adults. The weight loss achieved with CT-388 was clinically significant, with a placebo-adjusted mean weight loss of 18.8% (p < 0.001). At week 24, 100% of participants treated with CT-388 achieved >5% weight loss, 85% achieved >10% weight loss, 70% achieved >15% weight loss, and 45% achieved >20% weight loss. Treatment was well tolerated, with the most common adverse events being mild to moderate gastrointestinal events, consistent with the incretin class of drugs to which CT-388 belongs. All participants with prediabetes at baseline achieved normal glycemic status after 24 weeks of CT-388 treatment, while the glycemic status of participants treated with placebo remained largely unchanged during this period.

[0621] Efficacy: Robust, statistically significant, and clinically significant exposure-dependent weight loss effects were observed in the 8 mg and 22 mg groups (compared to placebo) (p<0.001). At week 12, the placebo-adjusted percentage change in weight from baseline (95% CI) was -9.3% (-5.22, -13.40)% and -11.5% (-7.88, -15.11)%, respectively. The effect of CT-388 22 mg persisted over an additional 12-week extension period (week 24): the placebo-adjusted percentage change in weight (95% CI) was -18.8% (-14.00, -23.6)% from baseline.

[0622] Over 24 weeks, weekly subcutaneous injections of CT-388 resulted in 18.8% of participants achieving a clinically significant and statistically substantial placebo-adjusted mean weight loss (p < 0.001). At week 24, 100% of participants treated with CT-388 achieved a weight loss of >5%, 70% achieved a weight loss of >15%, and 45% achieved a weight loss of >20%.

[0623] Glucose changes: In the subgroup of patients who were prediabetic at baseline, CT-388 treatment normalized blood glucose levels in all patients, demonstrating its significant impact on glucose homeostasis. Placebo patients remained largely unchanged over 24 weeks. All seven participants who were prediabetic at baseline achieved normal blood glucose levels after 24 weeks of CT-388 treatment (100%); one-quarter of the prediabetic participants treated with placebo achieved normal blood glucose levels (25%).

[0624] Safety: No new or unexpected safety signals were detected. Overall, CT-388 demonstrated similar efficacy to its drug.The safety and tolerability profile was consistent across the drug classes. No SAEs or GI-related TEAEs associated with severe treatment were observed in CT-388 participants. As expected, aggressive and steep upregulation resulted in a higher frequency of GI-related TEAEs during the upregulation phase. The incidence of GI-TEAEs tended to decrease during the extension phase, when most patients were at a stable dose.

[0625] Conclusion

[0626] The results are very encouraging for the further development of CT-388 for obesity and type 2 diabetes and highlight its potential to become a best-in-class therapy with durable weight loss and glucose control.

[0627] These results suggest that CT-388 has the potential to improve weight-related comorbidities and has beneficial effects on glucose metabolism / control in both individuals with and without T2D.

[0628] Example 4: Evaluation of the efficacy, safety and tolerability of once-weekly administration of CT-388 for 48 weeks in obese or overweight participants with at least one weight-related comorbidity. Randomized, double-blind, placebo-controlled, parallel-group, multicenter phase 2 study. Pre-sale information 43 / 65 pages 46 CN 121398835 A

[0629] This example describes a multicenter, randomized, double-blind, placebo-controlled, parallel-group dose-finding study to evaluate the efficacy and safety of CT-388 at low to high doses (4 mg to 24 mg).

[0630] This study will recruit approximately 450 participants who are obese (BMI ≥30 kg / m2) or overweight (BMI ≥27 and <30 kg / m2) and have at least one of the following weight-related comorbidities: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Participants with any type of diabetes, obesity associated with endocrine disorders (e.g., Cushing's syndrome), or using certain medications (e.g., chronic glucocorticoids) will be excluded.

[0631] This study will evaluate CT-388 at target doses of 4, 8, 12, 16, and 24 mg, which will be achieved via a fixed dosing regimen (4 mg) or dose escalation (8, 12, 16, and 24 mg). Treatment with CT-388 will begin with a starting dose of 2 mg or 4 mg. CT-388 will be administered as an SC injection via QW for 48 weeks.

[0632] Eligible participants will be randomly assigned to one of six treatment groups (CT 388 4, 8, 12, 16, or 24 mg or placebo) to recruit the same number of participants in each of the six arms (N=75 / arm) (Figure 19). Due to titration...The study drug dose and volume will be determined via a two-step randomization process, which will randomize participants in a 1:5 ratio to a volume-matched placebo and an active treatment at each target dose level. Randomization will be stratified according to the participant's sex (male vs. female). At each research center, efforts should be made to recruit a similar number of male and female participants. To avoid extreme imbalances in the two sexes in the study enrollment, the number of female participants will be limited to 70%.

[0633] During a three-week screening period prior to treatment, participants will sign an informed consent form (ICF) and undergo eligibility assessment. Upon confirmation of eligibility, participants will return for a Day 1 visit and will be randomized. Once randomized, participants will be considered enrolled in the study. Dosing of the study drug will begin on the same day as randomization.

[0634] The treatment period will consist of 48 weeks of treatment, divided into an upregulation period (day 1 before dosing to week 28) and a maintenance period (week 28 to week 48). The overall dosing regimen is shown in Figure 19.

[0635] During the accumulator phase, participants randomly assigned to 8, 12, 16, or 24 mg doses will undergo an accumulator phase, with their dose increased according to the treatment plan, aiming to increase the dose by four units per month (except for 2 mg to 4 mg, if applicable), and to reach the designated target dose at the end of the accumulator phase. If tolerability issues are observed, the algorithm shown in Figure 20 should be followed. The last point in time to reach the designated target dose is week 27.

[0636] The maintenance phase will begin in week 28 and end in week 48, with the last dose in week 47, and the designated target dose is expected to be maintained for 20 weeks. If participants experience tolerability issues, the algorithm shown in Figure 20 should be followed again.

[0637] Week 47 will be the last dose of the study drug. Week 48 will be the last treatment visit. Participants will return to the clinic in week 53 for a final safety follow-up visit.

[0638] During the study, all enrolled participants will receive dietary and physical activity guidance from a dietitian or equivalent representative, ideally monthly, and at least every 12 weeks during study visits (or by telephone where appropriate), and reinforced by research center staff during additional study visits. Participants will be encouraged to maintain a calorie deficit of approximately 500 kcal per day relative to estimated total energy expenditure (calculated once at randomization), and will be encouraged to engage in 150 minutes of physical activity such as walking per week. Participants will also be instructed to record their daily / weekly food intake, physical activity, and (if applicable) menstruation via a study diary, and their smoking / alcohol intake via a TLFB calendar, to assess their lifestyle patterns / programs and thus provide appropriate recommendations.

[0639] A.Objective

[0640] The primary objective of this study is to evaluate the effect of low, medium, and high doses of CT-388 QW injections, achieved through upregulation, on the percentage change in body weight compared to baseline after 48 weeks of treatment. (Instructions for Use, 44 / 65 pages, 47 CN 121398835 A)

[0641] Secondary objectives are:

[0642] ● To estimate the proportion of participants who experienced a weight loss of ≥5% compared to baseline after 48 weeks of CT-388 treatment;

[0643] ● To assess the effects of CT-388 on:

[0644] ○ Weight-related parameters (weight, BMI, waist-to-hip ratio, waist-to-height ratio, waist circumference, hip circumference, proportion of participants achieving specific weight and BMI thresholds); and

[0645] ○ Glucose metabolism (glycated hemoglobin A1 [HbA1c], fasting blood glucose, fasting insulin, C-peptide) and blood glucose status.

[0646] The safety objective was to evaluate the safety and tolerability of CT-388 compared to placebo over 48 weeks.

[0647] B. Study Endpoints

[0648] The primary efficacy endpoint was the percentage change (%) in body weight from baseline to week 48.

[0649] Secondary endpoints are:

[0650] a. Weight loss ≥5% from baseline to week 48;

[0651] b. Weight loss ≥10% from baseline to week 48;

[0652] c. Weight loss ≥15% from baseline to week 48;

[0653] d. Weight loss ≥20% from baseline to week 48;

[0654] e. Weight loss ≥25% from baseline to week 48;

[0655] f. Absolute change in weight (kg) from baseline to week 48;

[0656] g. Percentage change in weight (%) from baseline to week 48, categorized by obesity level;

[0657] h. Changes in the following weight-related parameters from baseline to week 48:

[0658] i. BMI (kg / m2);

[0659] ii. Waist circumference (cm), hip circumference (cm), and waist-to-hip ratio; and

[0660] iii. Waist-to-height ratio;

[0661] i. Changes in glucose metabolism markers from baseline:

[0662] i. HbA1c;

[0663] ii. Fasting blood glucose;

[0664] iii. Fasting insulin;

[0665] iv. Fasting C-peptide;

[0666] v. Fasting HOMA-IR; and

[0667] vi. Quantitative insulin sensitivity test index (QUICKI); and

[0668] j. Changes in glycemic status from baseline to week 48 based on fasting blood glucose and HbA1c.

[0669] The exploratory endpoint was:

[0670] a. Changes in the following cardiovascular risk factors, such as:

[0671] i. Systolic and diastolic blood pressure (mm Hg);

[0672] ii. Triglycerides (mg / dL);

[0673] iii. Non-high-density lipoprotein (HDL) cholesterol (mg / dL);

[0674] iv. HDL cholesterol (mg / dL);

[0675] v. Total cholesterol, low-density lipoprotein (LDL) cholesterol, and very low-density lipoprotein cholesterol (mg / dL); and

[0676] vi. NT-proBNP; Instructions for Use 45 / 65 pages 48 CN 121398835 A

[0677] b. Time to reach the final dose (weeks);

[0678] c. Time to reach the weight loss plateau (weeks), defined as a weight change ≤5% over a 12-week interval and all subsequent weeks;

[0679] d. CT-388 PK and the concentration of CT-388 metabolites (if applicable); and

[0680] e. Anti-drug antibodies and cross-reactivity to natural GLP-1 and GIP during treatment with CT-388.

[0681] Safety endpoints were:

[0682] a. Number of participants who experienced ≥1 TEAE, SAE, AE of special concern, or AE leading to discontinuation of the study drug;

[0683] b. TEAEs occurring in >10% of enrolled participants;

[0684] c. Number of participants with a history of hypoglycemia (grades 1, 2, and 3, according to ADA 2024);

[0685] d. Changes from baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) and Patient Health Questionnaire-9 (PHQ-9); and

[0686] e. Changes in safety laboratory values, vital signs, and electrocardiogram (ECG).

[0687] C. Basic Principles of Study Design

[0688] This study (CT-388-103) aimed to evaluate the efficacy and safety of CT-388 at different doses in obese or overweight adult patients with at least one of the following weight-related comorbidities: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, but excluding T2D. The study utilized a randomized, double-blind, parallel, placebo-controlled, multicenter design to rigorously assess the efficacy and safety of CT-388 versus placebo SC QW administration in combination with a low-calorie diet and increased physical activity. The placebo arm served as the control arm, representing the most rigorous test for evaluating treatment efficacy in complex patient populations. To ensure that all participants (including placebo participants) received standard care for obesity management, the study design included guidance on diet and lifestyle provided according to local standards and guidelines provided in the protocol throughout the study period.

[0689] The study lasted 56 weeks, includingThe study included a 3-week screening period, a 48-week treatment period, and a 5-week safety follow-up period (post-treatment). The primary endpoint was defined as the percentage change in body weight from baseline to week 48. A 48-week treatment duration was required to fully assess all doses of CT-388 (including 24 mg) as this allowed sufficient time to gradually titrate longer periods at each dose level before upregulation (i.e., maintaining a given dose for 4 weeks). Therefore, the 48-week treatment duration consisted of two periods: an upregulation period (day 1 pre-dose to week 28) and a maintenance period (week 28 to week 48).

[0690] During the upregulation phase, CT-388 / placebo was initiated at a dose of 2 mg or 4 mg, with subsequent planned dose increases to target levels (8, 12, 16, and 24 mg), planned at least four-week intervals during the first 24 weeks of treatment. This cautious titration approach was expected to provide participants with sufficient time to adequately adapt to each dose. Nevertheless, to further maximize the number of subjects who can reach the target randomized dose, this study allows for an additional four weeks (i.e., up to week 27) to upregulate and achieve the maximum tolerated dose for each subject. During the maintenance period, while participants are expected to maintain their target / maximum tolerated dose until the end of the treatment period (i.e., at least 20 weeks at the final dose), a pharmacological holiday or dose reduction may be performed for safety or tolerability reasons.

[0691] The follow-up phase (5-week non-treatment period) will provide safety follow-up and allow for a better understanding of changes in weight and other relevant metabolic parameters after treatment cessation.

[0692] Therefore, the study duration of 56 weeks (48 weeks for the treatment period) is tailored to fully assess the weight loss trajectory, the durability of remission, and the maintenance of weight loss over time, and to collect valuable data to characterize the long-term safety and tolerability of CT-388. These findings will contribute to the implementation of subsequent Phase 3 development plans.

[0693] D. Inclusion Criteria

[0694] Participants who meet all of the following criteria prior to randomization may be enrolled in the study:

[0695] a. Male or female, aged 18 to 75 years at the time of informed consent

[0696] b. BMI ≥30.0 ​​kg / m2 or BMI ≥27.0 and <30.0 kg / m2, and have been previously diagnosed with at least one of the following weight-related comorbidities, such as:

[0697] i. Prediabetes: as defined in the 2024 ADA Standards of Diabetes Care

[0698] ii. Hypertension: defined as hypertension currently treated with antihypertensive medication, or systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥130 mm Hg.iii. Blood pressure ≥80 mm Hg

[0699] iii. Dyslipidemia: defined as currently being treated with lipid-lowering agents for dyslipidemia, or based on central laboratory values, low-density lipoprotein (LDL) ≥160 mg / dL (4.1 mmol / L) or triglycerides ≥150 mg / dL (1.7 mmol / L), or high-density lipoprotein (HDL) <40 mg / dL (1.0 mmol / L) for men or <50 mg / dL (1.3 mmol / L) for women

[0700] iv. Previously diagnosed with obstructive sleep apnea, or

[0701] v. Previously diagnosed with cardiovascular disease (e.g., ischemic cardiovascular disease, New York Heart Association (NYHA) functional class I or II heart failure)

[0702] c. Has ≥1 self-reported experience of diet / exercise failure.

[0703] E. Exclusion Criteria

[0704] Participants who meet any of the following criteria prior to treatment will not be enrolled in the study.

[0705] Diabetes-related

[0706] a. A history or diagnosis of any type of diabetes (e.g., type 1, type 2, pregnancy), or a history of ketoacidosis or hyperosmolar state.

[0707] b. Laboratory evidence of diabetes based on fasting blood glucose or HbA1c during the screening period.

[0708] Note: A diagnosis of prediabetes (if determined by fasting blood glucose or HbA1c) is not exclusive, but participants must not receive any type of glucose-lowering treatment (medications or dietary supplements), including but not limited to metformin, berberine, etc.).

[0709] Obesity-related

[0710] c. Having undergone any of the following surgeries within 1 year prior to the screening visit or planned to undergo during study participation: LAP-BAND®, gastric balloon, duodenal cannulation, skin resurfacing, liposuction, and / or abdominoplasty.

[0711] Other medical-related

[0712] d. Having a known clinically significant or active gastric emptying disorder (e.g., severe gastroparesis or gastric outlet obstruction, intestinal obstruction, or any GI motility disorder); malabsorption, including chronic constipation / diarrhea, celiac disease, inflammatory bowel disease, or bowel resection; or long-term use of medications that directly affect GI motility (e.g., anticholinergics, serotonin antagonists, opioids).

[0713] e. Having had or currently having chronic pancreatitis within 6 months prior to screening, or having acute pancreatitis.

[0714] f. History of gallstones and / or acute cholecystitis complications within 6 months after screening (excluding previous cholecystectomy).

[0715] g. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and / or diastolic blood pressure ≥100 mm Hg). (See instruction manual 47 / 65)Page 50 CN 121398835 A Participants receiving antihypertensive medication must have received stable dose treatment for ≥2 months prior to the screening visit.

[0716] h. Any of the following cardiovascular conditions within 6 months prior to screening: hospitalization due to congestive heart failure, myocardial infarction, cerebrovascular accident (stroke), transient ischemic attack, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention (including patients who are planned and / or expected to undergo percutaneous transluminal coronary angioplasty [PTCA] during study participation, such as patients with prior angiographic evidence that PTCA may be necessary).

[0717] i. NYHA functional classification III or IV congestive heart failure.

[0718] j. Personal or family history of long QT syndrome, family history of sudden death of a first-degree relative (parent, sibling, or child) before age 40, or personal history of unexplained syncope within the past year.

[0719] k. Having uncontrolled thyroid disease, defined as active symptoms (e.g., palpitations, somnolence, weight gain / loss) and / or thyroid-stimulating hormone (TSH) levels exceeding the normal reference range of a central laboratory at the screening visit.

[0720] Note: Participants receiving adequate treatment for hypothyroidism may be included, provided they are clinically asymptomatic and their thyroid hormone replacement dose has remained stable for ≥2 months prior to the screening visit.

[0721] l. Having obesity induced by other endocrine disorders (e.g., Cushing's syndrome, acromegaly, undertreated hypothyroidism) or diagnosed with a monogenic or syndromic form of obesity (e.g., melanocyte-stimulating hormone 4 receptor deficiency or Pu-Wei syndrome).

[0722] m. Having a history / diagnosis of major depressive disorder, or any other major mental illness (e.g., schizophrenia, bipolar disorder, eating disorder, other severe mood, anxiety, or hyperactivity disorder) within 2 years after the screening visit.

[0723] Note: Prospective participants whose disease status is considered stable and who are expected to remain stable in depression or anxiety throughout the study may be considered for inclusion only if they have been adequately controlled for ≥6 months with a stable dose of a selective serotonin reuptake inhibitor (other than paroxetine) prior to the screening visit and are expected to continue to be enrolled at the same dose throughout the study. Participants using other types of antidepressants / mood stabilizers were excluded from this study because many participants were associated with weight changes (see Section 7.3.2 for a more detailed list of contraindicated medications).

[0724] n. PHQ-9 score ≥15 at the screening visit and Day 1.

[0725] o. History of any lifelong suicide attempt or suicidal behavior within 30 days prior to the screening visit.

[0726] p. C-SSRS assessed at the screening visit or Day 1.Suicidal ideation, and is identified as:

[0727] vii. Answering "yes" to question 4 (active suicidal ideation with some intention to act, without a specific plan), or

[0728] viii. Answering "yes" to question 5 (active suicidal ideation with a specific plan and intention) in the "Suicidal Ideation" section of the C-SSRS, or

[0729] ix. Answering "yes" to any suicide-related behavior (actual attempt, interrupted attempt, aborted attempt, preparation of action or behavior) in the "Suicidal Behavior" section of the C-SSRS

[0730] and having the idea or behavior within the past month.

[0731] q. Having any blood condition that may interfere with HbA1c measurement (e.g., hemolytic anemia, sickle cell disease, other hemoglobinopathies).

[0732] r. Family or personal history of medullary thyroid carcinoma, or a genetic predisposition to medullary thyroid carcinoma (i.e., thyroid C-cell hyperplasia or multiple endocrine neoplasia type 2A or 2B).

[0733] ​​s. ECG results repeated at the screening visit and on day 1:

[0734] x. Indications of active heart disease or clinically significant variants / abnormalities as determined by the investigator that may interfere with the interpretation of ECG changes during the study; Specification 48 / 65 pages 51 CN 121398835 A

[0735] xi. QTc (Fridericia) interval ≥450 ms for men and ≥470 ms for women;

[0736] xii. Resting heart rate <45 bpm or >100 bpm; or

[0737] xiii. Any other pathological rhythm.

[0738] t. Any of the following results were present during the screening period as determined by the central laboratory:

[0739] xiv. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) >3.0 × the upper limit of normal (ULN) of the reference range

[0740] xv. Alkaline phosphatase (ALP) >1.5 × the ULN of the reference range

[0741] xvi. Total bilirubin >1 × the ULN of the reference range

[0742] xvii. Amylase or lipase >2 × the ULN of the reference range

[0743] xviii. Calcitonin ≥20 ng / L

[0744] xix. Estimated glomerular filtration rate (eGFR) <60 mL / min / 1.73 m2 as obtained by the 2021 CKD-EPI creatinine equation

[0745] xx. Fasting plasma triglycerides ≥500 mg / dL

[0746] xxi. Acute or chronic viral hepatitis (based on the presence of hepatitis B surface antigen [HbsAg] or HCV RNA)

[0747] xxii. HIV antibody positive at screening

[0748] xxiii. Hemoglobin value <11 g / dL (male) or <10 g / dL (female)

[0749] xxiv. White blood cell (WBC) < lower limit of normal (LLN) of the reference range

[0750] xxv. Platelet count < LLN of the reference range

[0751] Previous / concomitant medication

[0752] u. Currently receiving or having received chronic (consecutive >14 days) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular or inhaled formulations) within three months prior to the screening visit, or having evidence of a significant active autoimmune disorder (e.g. lupus or rheumatoid arthritis) requiring (within the past 3 months) or deemed necessary by the investigator to use systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular or inhaled formulations) during study participation.

[0753] F. Dietary and Physical Activity Guidance

[0754] All enrolled participants in this study will receive guidance from a dietitian or equivalent representative according to local standards, ideally monthly, and at least every 12 weeks during study visits at days 1 and weeks 12, 24, 36, and 48 (or by telephone where appropriate). The dietary and exercise goals identified during the lifestyle guidance and the importance of adhering to the lifestyle components of the trial will be reinforced by the researchers at each trial contact. Participants will be instructed on how to record their physical activity and food intake in a study-provided diary to facilitate review and appropriate guidance during their study visits.

[0755] a. Dietary guidance will include recommendations on healthy food choices and will focus on restricting calorie intake using a low-calorie diet with the following macronutrient composition:

[0756] xxvi. Up to 25% of energy from fat

[0757] xxvii. Approximately 25% of energy from protein

[0758] xxviii. Approximately 50% of energy from carbohydrates.

[0759] b. It is recommended that the energy deficit be approximately 500 kcal / day compared to the participant's estimated total energy expenditure.

[0760] xxix. Total energy expenditure (TEE) will be calculated using the weight planner from the National Institute of Diabetes, Digestive and Kidney Diseases (provided by CN 121398835 A NIH, pages 49 / 65 of the manual), taking into account the participant's weight and physical activity level.

[0761] c. Participants with significantly suppressed appetite must be advised to consume at least 900 kcal / day, with an emphasis on adequate protein intake (high-protein guarantee / enhanced dietary alternatives may also be provided).

[0762] d. Regular physical activity is encouraged (150 minutes of physical activity per week, e.g., walking).

[0763] e. A low-calorie diet should be continued during randomization and throughout the treatment period.

[0764] f. If a BMI ≤ 22 kg / m2 is achieved, the recommended energy intake should be recalculated for the remainder of the trial, with no kcal deficit.

[0765] G. Definition of Glucose Status

[0766] Participants in this study will be assessed for their glucose status and categorized as normoglycemic, prediabetic, or diabetic as defined by ADA Standard of Care (ADA 2024).

[0767] An initial glucose assessment will be performed during the screening phase to determine the status of normoglycemic, prediabetic, or overt diabetes. This assessment will utilize measurements of fasting blood glucose and HbA1c. If the screening results show a clear diagnosis of diabetes, characterized by a fasting blood glucose level ≥126 mg / dL (7.0 mmol / L) or an HbA1c value ≥6.5% (48 mmol / mol), the participant will be excluded.

[0768] Only participants with normal blood glucose or prediabetes will be enrolled in the study. If any participant is diagnosed with T2D during the screening process, they will be instructed to consult their primary care physician for appropriate management.

[0769] Throughout the 48-week treatment phase, the study will maintain regular monitoring of blood glucose status. This monitoring will be facilitated by regular checks of fasting blood glucose or HbA1c levels.

[0770] Table 22. Screening and diagnostic criteria for prediabetes and diabetes (definition of blood glucose status)

[0771]

[0772] a. For all these tests, the risk persists, extends below the lower limit of the range, and becomes disproportionately increased at the upper limit of the range.

[0773] b. In the absence of clear hyperglycemia, the diagnosis requires two abnormal test results from the same sample or two separate samples.

[0774] c. Diagnosis should only be made in patients with typical symptoms of hyperglycemia or a hyperglycemic crisis.

[0775] Adapted from Tables 2.2 and 2.5 in the complete 2024 Standard of Care (ADA 2024).

[0776] H. Clinical Assessment

[0777] Weight and BMI

[0778] Weight measurement should be performed in a consistent manner, using a calibrated electronic scale capable of measuring weight in kilograms (kg) and accurate to one decimal place.

[0779] All weights of a given participant should be measured using the same scale at approximately the same time in the morning after the bladder contents have been emptied, whenever possible.

[0780] Weight must be measured on an empty stomach. If the participant is not fasting, the measurement should be taken on the allowable visit window instructions, page 50 / 65, 53 CN 121398835 A.Participants will be called to a new visit to measure their fasting weight.

[0781] Waist and Hip Circumference

[0782] Waist circumference should be measured at the horizontal plane and at the midpoint between the lower edge of the last palpable rib and the top of the iliac crest.

[0783] a. Measurements should be taken at the end of a normal expiration using a non-stretchable measuring tape. The measuring tape should be laid flat on the skin without compressing the soft tissue.

[0784] b. Waist circumference should be measured twice, and the results should be rounded to the nearest 0.5 cm. The measuring tape should be removed between the two measurements. Both measurements will be recorded in the eCRF. If the difference between the two measurements exceeds 1 cm, the set of measurements should be discarded and the two measurements repeated.

[0785] Vital Signs

[0786] Vital signs (temperature, blood pressure, pulse, respiratory rate) will be obtained at each study visit. Vital signs will be checked after the participant has rested for ≥5 minutes in a sitting, supine, or semi-recumbent position. For each parameter, three measurements will be taken using the same arm, preferably the non-dominant arm, with recordings spaced at least 1 minute apart. If possible, blood pressure must be measured using an automated blood pressure monitor. If blood pressure and pulse are measured separately, pulse should be measured before blood pressure. Participants are advised to avoid caffeine, smoking, and physical activity for 1 hour prior to vital sign measurements during all visits to the research center / clinic.

[0787] PK Blood Samples

[0788] Pre-dose samples collected from all enrolled study participants will be used to analyze CT-388 plasma concentrations to determine trough CT-388 levels throughout the study drug administration period.

[0789] In addition, subgroups of participants (i.e., those willing to provide informed consent and able to return to the research center for multiple blood draws within a week) will undergo additional PK sampling during the 48-week treatment period for population PK post-dose assessment. Participants may choose from three different post-dose PK sampling time points for each of the following three time periods: 24 to 48 hours (i.e., 1 to 2 days) after administration, 48 to 72 hours (i.e., 2 to 3 days) after administration, or 72 to 96 hours (i.e., 3 to 4 days) after administration, without duplication:

[0790] 1) Week 1 to Week 12;

[0791] 2) Week 13 to Week 28; and

[0792] 3) Week 29 to Week 48.

[0793] Participants must choose a different time point for each of the three time periods. This method ensures the collection of PK data across different ranges, providing a more comprehensive understanding of PK variability between individuals and over time.

[0794] Samples from participants receiving a placebo will not be evaluated immediately but will be retained where appropriate.For subsequent analysis. Samples will not be analyzed in real time, but will be analyzed in batches throughout the study.

[0795] Plasma concentrations obtained at these time points will be used for population PK, PD, and safety analyses.

[0796] Metabolites of CT-388 can be measured by a validated specific liquid chromatography-tandem mass spectrometry (LC-MS / MS) assay or, where appropriate, other methods suitable for the purpose. When assays are available, sufficient samples should be stored so that CT-388 metabolites in these samples can be measured during the study. Unused sample material can be used for current CT-388 assay improvement purposes and for the evaluation of exploratory plasma biomarkers.

[0797] Any PK samples remaining after the specified analysis can also be used for additional assay development / validation experiments (e.g., metabolite identification, ADA assay validation, or exploratory plasma biomarkers).

[0798] Dosage Titration

[0799] The dose for each participant in the low-to-high dose CT-388 treatment will be incremented as shown in Figure 19. Dosage escalation may occur at or after the designated up-regulation time, but not before. Instructions for Use, pages 51 / 65, CN 121398835 A

[0800] The last up-regulation / re-stimulation time is week 27. Figure 20 should be followed to help participants maintain their final dose during the maintenance period (week 28 until the first administration of the study drug at week 47).

[0801] Participants experiencing GI-related symptoms should be managed according to Figure 20.

[0802] Participants randomly assigned to low- to high-dose CT-388 treatment need to tolerate at least 0.2 mL to continue using the study drug. If the investigator deems that a participant cannot tolerate 0.2 mL despite being given additional time to adjust to that dose level and having taken all symptom-relieving measures to address tolerance issues, the individual will discontinue administration of their assigned study drug. Adverse Events

[0803] An AE is any adverse and unexpected sign (including abnormal laboratory findings), symptom, or illness that is temporarily associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. A TEAE is defined as an AE that worsens or begins at or after the first administration of the study drug.

[0804] All AEs will be recorded throughout the study period (i.e., from screening until 45 days after the last follow-up visit or the last administration of the study drug, whichever is later), regardless of their severity or how they are identified (e.g., voluntary, induced, or recorded during a physical examination).

[0805] Participants' AEs will be tracked for resolution by asking them if they have a persistent AE, up to the earlier of the AE resolution or the last study visit.

[0806] Researchers will score the severity / intensity of each AE. Researchers may refer to the National Cancer Institute-Common Terminology Standard for Adverse Events (CTCAE) version 5.0. CTCAEs are graded from 1 to 5, with a unique clinical description for the severity of each AE. A general grading (severity / intensity) scale for those events not specifically listed is provided at the beginning of the CTCAE reference document.

[0807] I. Data Analysis and Statistical Considerations

[0808] Once the protocol is approved by the regulatory agency and before database locking (unblinding), a separate statistical analysis plan (SAP) will be prepared. This document will provide further details on the definition of analytical variables and analytical methods to address all study objectives. SAP will be used as a supplement to the protocol and will supersede it in case of discrepancies.

[0809] Statistical evaluation will be performed using SAS® software version 9.4 or later (SAS Institute, Cary, NC). All data will be listed and summary tables will be provided. Summary statistics will be presented by treatment group. Continuous variables, including measurements, changes from baseline, and percentage changes, will be summarized using observations, mean, standard deviation, median, minimum, and maximum values. Categorical variables will be summarized using counts and percentages for each category. Unless otherwise stated, treatment differences will be presented along with 95% confidence intervals where appropriate.

[0810] p-values ​​will be rounded to three decimal places. Values ​​less than 0.001 will be presented as "<0.001". Statistical significance will be determined by comparing p-values ​​to significance levels [0.035 (or 0.05), 0.01, or 0.001]. Comparisons will not be rounded.

[0811] Sample Size

[0812] For percentage changes in body weight from baseline to week 48, assuming a standard deviation of 10%, ≥91% efficacy will be achieved for each of the 60 complete subjects in each treatment arm to detect a true difference of at least 6.4% between the CT-388 dose and placebo. The significance level was determined by a two-sample t-test, which was two-tailed and had a significance level of 3.5%. Compared with placebo, the overall type 1 error rate for the primary efficacy endpoint in the five dose groups in this study will be approximately 13%.

[0813] A total of approximately 450 subjects will be randomly assigned on average to receive placebo, 4, 8, 12, 16, and 24 mg CT-388, which will be achieved through a fixed dosing regimen and upregulation over 48 weeks of treatment, resulting in 75 subjects in each treatment group. Assuming a dropout rate of up to 20% during the treatment period, this will ensure that ≥360 subjects (i.e., ≥60 subjects per treatment group) complete the 48 weeks of treatment.Weekly treatment period.

[0814] Randomization

[0815] The purpose of randomization is to achieve the same number of participants (N=75 / arm) across 6 treatment arms: placebo, CT-388 4, 8, 12, 16, and 24 mg. Due to the titration protocol and the volume of the study drug dose, this will be achieved through a 2-step randomization process, whereby participants are randomly assigned in a 1:5 ratio to a volume-matched placebo group and to active treatment for each of the target dose levels:

[0816] Step 1. Participants are randomly assigned in a 1:1:1:1:1 ratio to 5 target dose levels (CT-388 4, 8, 12, 16, or 24 mg). Throughout the study, all participants at the same target dose level (placebo or active drug) will receive the same volume of study drug at each injection of the planned dose level. This step will be blinded so that neither the participants nor the researchers will be aware of the target dose level allocation.

[0817] Step 2. At each target dose level, participants will be randomly assigned to the placebo group and the active treatment group at a ratio of 1:5. This step will be blinded so that neither the participants nor the investigators will know whether a participant will receive a placebo or the active treatment.

[0818] Through this randomization, staff and participants will not know at the time of randomization which dose group a participant has been assigned to, nor will they know whether they will receive CT 388 or a placebo. However, the research center and research center staff will know the volume of the study drug to be administered at each visit. Randomization will be performed by IRT.

[0819] Randomization will be stratified by sex (male and female). In addition, to avoid extreme imbalance between the two sexes in the study, the number of female participants will be limited to 70%.

[0820] For all summaries and analyses performed by treatment arm, placebo participants will be pooled together to form the placebo group.

[0821] Analysis Sets

[0822] The analysis sets are detailed in the following sections. A summary of the analysis sets will be provided. Individual analysis set markers will also be listed.

[0823] a. Full Analysis Set: All randomized participants will be included in the Full Analysis Set (FAS) based on the assigned randomized treatment. The FAS will be used to summarize all baseline characteristics and demographic data. The FAS will also be used for all efficacy and PD analyses.

[0824] b. Safety Set: All randomized participants who received ≥1 dose of the investigational drug will be included in the safety set based on the actual treatment received. The safety cohort will be used to summarize all safety endpoints.

[0825] c. PK Set: All randomized subjects who received ≥1 dose of CT-388 and had ≥1 effective plasma CT-388 concentration will be included in the PK set. The PK set will be used for population PK analysis.

[0826] Example5: A randomized, double-blind, placebo-controlled, parallel-group, multicenter phase 2 study evaluating the efficacy, safety, and tolerability of once-weekly subcutaneous administration of CT-388 for 48 weeks in overweight or obese participants with type 2 diabetes mellitus

[0827] This example describes a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of CT-388 at low to high doses (4, 8, 16, and 24 mg) in obese or overweight patients with T2DM.

[0828] Approximately 360 participants who were overweight (defined as BMI ≥25 and <30 kg / m2) or obese (defined as BMI ≥30 kg / m2) and had T2DM with inadequate glycemic control (defined as HbA1c ≥7.0% and ≤10.5%) will be recruited. Participants must have been diagnosed with type 2 diabetes mellitus (T2DM) at least six months prior to treatment and have managed T2DM by diet and exercise alone or by metformin or a sodium-glucose cotransporter 2 (SGLT-2) inhibitor as monotherapy or in combination. Antihyperglycemic agents must have been at a stable dose for at least three months prior to treatment.

[0829] Participants with other conditions associated with weight gain or elevated glucose levels (e.g., Cushing's syndrome, type 1 diabetes) were excluded.

[0830] CT-388 will be administered subcutaneously (SC) via QW. CT-388 will be evaluated at final target doses of 4, 8, 16, and 24 mg achieved through dose escalation for a total treatment duration of 48 weeks. Treatment with CT-388 will begin with a starting dose of 2 mg or 4 mg. In addition, the potential efficacy of low-dose (2 mg and 4 mg) CT-388 for glycemic control during a 12-week treatment period will be evaluated.

[0831] Eligible participants will be randomly assigned to one of five treatment groups (CT-388 4, 8, 16, 24 mg or placebo) to recruit the same number of participants in each group (N=72 / group). This will be achieved via a two-step randomization process due to the titration protocol and the volume of the study drug dose, which will randomize participants in a 1:4 ratio to the active treatment at a volume-matched placebo and target dose levels, stratified by participant sex (male vs. female), HbA1c value at screening (≤8.5% or >8.5%), and BMI <35 or ≥35. At each research center, efforts should be made to recruit a similar number of male and female participants to avoid extreme gender imbalances in the study.

[0832] The screening period can be ≤21 weeks.Participants will be instructed to begin recording data in a diary to collect information about their food intake, exercise, blood glucose levels, and menstruation (if applicable). This data will be collected via a mobile application or a paper diary and will support the assessment of potential safety issues (e.g., hyperglycemia or hyperglycemic events), discussions related to type 2 diabetes education, and lifestyle management. This data collection will continue throughout the study participation period.

[0833] After the screening period, eligible participants will enter a two-week introductory period to confirm their eligibility, undergo an MRI (if applicable), and begin monitoring their blood glucose stability.

[0834] From the start of the introductory period and throughout the study duration, all eligible participants will self-monitor their fasting blood glucose levels at least three times a week and as needed based on symptoms; using a study-specific blood glucose meter and spare parts provided to each participant.

[0835] Participants who provide consent will undergo their baseline MRI.

[0836] After the two-week introductory period, participants will return for a Day 1 visit. Upon eligibility confirmation, participants will be randomly assigned. At this point, participants will be considered enrolled in the study and will enter the treatment period. Following randomization and pre-dosing procedures, administration of the study drug will begin. The treatment period will last 48 weeks, divided into an upregulation period (day 1 before dosing to week 28) and a maintenance period (week 28 to week 48).

[0837] The study drug will be administered subcutaneously once weekly. Participants are not permitted to self-administer the study drug and must return to the clinic for administration. If a clinic visit is not feasible, a home nurse visit may be arranged. Ideally, dosing will be performed on the same day at the same time throughout the study period.

[0838] During the upregulation period, participants will have their dose increased (Figure 21) to achieve the specified target dose by following the schedule specified in the protocol. Participants assigned to the low target dose treatment group (4 mg and 8 mg) will begin CT-388 treatment with 2 mg or 4 mg, respectively, with dose increases following the initial 12 weeks of treatment. Participants assigned to the medium (16 mg) and high (24 mg) doses of CT-388 will begin treatment with 2 mg over the first 4 weeks, increasing by 4 mg monthly thereafter until the designated dose is reached. If tolerability issues are observed, the algorithm shown in Figure 20 should be followed. The last point in time when a participant can reach the designated target dose is week 27.

[0839] The maintenance period begins at week 28 and ends at week 48, with the last dose at week 47. The expectation during the maintenance period is that the achieved dose will be maintained for 20 consecutive weeks.Weeks. If a participant experiences tolerance issues, the algorithm shown in Figure 20 on pages 54 / 65 of the instruction manual, CN 121398835 A, should be followed. If a participant experiences significant weight loss (BMI ≤ 22 kg / m2), the calorie deficit should be discontinued.

[0840] In addition to weekly self-monitoring of fasting blood glucose, participants will undergo five 7-point self-monitoring blood glucose (SMBG) assessments during the study period: during the introductory period (days -14 to 1 before administration), at week 12, and at the beginning and end of the maintenance period (weeks 28 to 29 and 47 to 48). If hypoglycemia or hyperglycemia is detected based on glucose self-monitoring or SMBG, the participant must notify the research center for appropriate follow-up. Participants with severe persistent hyperglycemia may begin resuscitation therapy. During the study, all participants will be monitored for safety or tolerance issues, including but not limited to hyperglycemia, hypoglycemia, tachycardia, and liver and kidney injury. If safety or tolerability issues are observed, dose adjustments may be made, and participants may discontinue the study drug if any discontinuation criteria are met.

[0841] Blood samples for population pharmacokinetic analysis will be collected from selected participants during specific planned visits.

[0842] Enrolled MRI: Participants at selected sites will undergo whole-body MRI to assess body composition, visceral fat, and cerebral perfusion. Two MRIs will be performed during the study: during the introductory period and at the end of the treatment period. Week 47 will be the last dose of the study drug. Week 48 will be the last treatment period visit; participants will return to the clinic for a safety follow-up visit in week 53.

[0843] During the study, all enrolled participants will receive dietary and exercise guidance from a dietitian or an equivalently qualified representative. Guidance will be provided based on participant data collected via a mobile application or paper diary and will ideally be provided monthly, and at least every 12 weeks during study visits, or via telephone where appropriate. Participants will be encouraged to maintain an appropriate T2DM diet and a calorie deficit of approximately 500 kcal / day relative to their estimated total energy expenditure, and will be encouraged to engage in 150 minutes of physical activity per week.

[0844] For the purpose of fully evaluating all doses of CT-388 (including the 24 mg dose), 48 weeks of treatment are required to allow sufficient time for gradual titration at each dose level for a longer period before upregulation (i.e., at least 4 weeks at a given dose). Therefore, the 48-week treatment duration consists of two periods: an upregulation period (day 1 to week 28) and a maintenance period (week 28 to week 48).

[0845] During the upregulation phase, CT-388 or placebo will be administered at a dose of 100 kcal / day.Starting with a dose of 2 mg or 4 mg, subsequent planned dose increases to target levels (4, 8, 16, and 24 mg) are planned at intervals of at least 4 weeks over the first 24 weeks of treatment. This cautious titration approach is expected to provide participants with sufficient time to adequately adapt to each dose. Nevertheless, to maximize the number of subjects who can reach the target randomized dose, the study design allows for the use of an additional four weeks (i.e., up to week 27) for upregulation and to achieve the maximum tolerated dose for each subject. Pharmacological holidays or dose reductions may be performed for safety or tolerability reasons.

[0846] Furthermore, the first 12 weeks of treatment will be used to assess the effects of low-dose CT-388 (2 mg and 4 mg) on ​​participants with T2DM and to support the determination of the minimum effective dose for glucose metabolism markers and the effect of slow upregulation on weight trajectory.

[0847] During the maintenance period, while participants are expected to maintain their target / maximum tolerated dose until the end of the treatment period (i.e., at least 20 weeks at the final dose), a pharmacological holiday or dose reduction may be performed for safety or tolerability reasons.

[0848] The follow-up period (five-week non-treatment period) will provide safety monitoring and allow for a better understanding of changes in weight and other relevant metabolic parameters after treatment cessation.

[0849] Therefore, the study duration of 57 weeks (48 weeks for the treatment period) was tailored to fully assess the weight loss trajectory and its impact on HbA1c; the durability of remission; the maintenance of weight loss and HbA1c control over time; and to collect valuable data to characterize the long-term safety and tolerability of CT-388 in participants with T2DM. These findings will contribute to the implementation of subsequent Phase 3 development plans.

[0850] Inclusion Criteria

[0851] Participants who meet all of the following criteria prior to randomization are eligible for enrollment in the study.

[0852] a. Male or female, aged between 18 and 75 years at the time of providing signed informed consent.

[0853] b. BMI ≥25.0 kg / m2 at screening and Day 1 visit.

[0854] c. Diagnosed with T2DM according to the World Health Organization classification or other locally applicable criteria for at least 6 months prior to screening.

[0855] d. HbA1c ≥7% and ≤10.5% at screening and entry visit.

[0856] e. T2DM managed by diet and exercise alone, or managed by diet and exercise alone or by metformin or sodium-glucose cotransporter 2 (SGLT-2) inhibitors as monotherapy or in combination, according to the approved local label.Participants on inhibitor therapy must maintain stable therapy for >3 months prior to the screening visit

[0857] f. Have ≥1 self-reported failure of a weight loss diet / exercise.

[0858] g. Women of childbearing potential (WOCBP) must agree to abstain from sexual intercourse (avoiding heterosexual intercourse) or use a contraceptive method with an annual failure rate <1% during the treatment period and for 45 days after the last dose of CT-388.

[0859] Exclusion Criteria

[0860] Participants who meet any of the following criteria prior to randomization will not be enrolled in the study.

[0861] a. Have type 1 diabetes mellitus (T1DM), a history of ketoacidosis or hyperosmolar state / coma, or any other type of diabetes other than T2DM.

[0862] b. Have experienced one or more grade 3 hypoglycemic episodes or unconscious hypoglycemia within six months prior to screening.

[0863] c. At least two confirmed fasting self-monitored blood glucose values ​​>270 mg / dL within two non-consecutive days between screening and randomization.

[0864] d. History of or current presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy requiring acute treatment based on dilated fundus examination by an ophthalmologist or optometrist between screening and randomization.

[0865] e. Clinically significant evidence of active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea).

[0866] f. Treatment with any other antihyperglycemic agent other than metformin or SGLT-2, including but not limited to dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) or GLP-1 / glucagon-like peptide-1 receptor agonist (GIP-RA), sulfonylureas, and islet amyloid analogues.

[0867] g. Self-reported weight change >5 kg within three months after the screening visit.

[0868] h. Any unbalanced / extreme diet, such as very low calorie, low carbohydrate, very high protein, ketogenic, or intermittent diets, within three months after the screening visit, or plans to follow such diets during the study.

[0869] i. Currently or within the most recent three months prior to screening, involved in an organized weight loss program.

[0870] j. Has a prior or planned surgical treatment or surgery (any type) for obesity (excluding liposuction or abdominoplasty if performed more than one year prior to screening).

[0871] k. Has been treated with any medication, device, dietary supplement, or any over-the-counter preparation (approved or investigational) that promotes weight loss within six months after the screening visit, or plans to receive such treatment during study participation.

[0872] l. Has a known clinically significant or active gastric emptying disorder (e.g., severe gastroparesis or gastric outlet obstruction).Page 56 / 65 59 CN 121398835 A Obstruction, intestinal obstruction or any gastrointestinal (GI) motility disorder); malabsorption, including chronic constipation / diarrhea, celiac disease, inflammatory bowel disease, bowel resection; or long-term use of medications that directly affect GI motility (e.g., anticholinergics, 5-HT3 antagonists, opioids).

[0873] m. Has had or currently has chronic pancreatitis within six months prior to screening, or has acute pancreatitis.

[0874] n. Has a history of gallstones and / or acute cholecystitis complications within six months after screening (excluding a history of cholecystectomy). Note: Participants who have undergone surgical removal of gallstones and / or gallbladder without long-term complications are eligible, provided that the surgery was performed at least three months prior to screening.

[0875] o. Has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and / or diastolic blood pressure ≥100 mm Hg). Participants receiving antihypertensive medication must have been on a stable dose for ≥1 month prior to the screening visit.

[0876] p. Elevated resting pulse rate (>100 bpm) at the screening visit and on Day 1

[0877] q. Any of the following cardiovascular conditions within the six months prior to screening: congestive heart failure, myocardial infarction, cerebrovascular accident (stroke), transient ischemic attack, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention (including patients who are planned and / or expected to undergo percutaneous transluminal coronary angioplasty [PTCA] during study participation, such as patients with prior angiographic evidence that PTCA may be necessary).

[0878] r. New York Heart Association functional class III or IV congestive heart failure.

[0879] s. Personal or family history of long QT syndrome, family history of sudden death of a first-degree relative (parent, sibling, or child) before age 40, or personal history of unexplained syncope within the past year.

[0880] t. Having uncontrolled thyroid disease, defined as having active symptoms (e.g., palpitations, weight gain / loss) and / or having thyroid-stimulating hormone (TSH) levels exceeding the normal reference range of a central laboratory at the screening visit. Note: Participants receiving thyroid hormone replacement therapy may be included provided they are clinically asymptomatic and their TSH replacement dose has remained stable for ≥2 months prior to the screening visit.

[0881] u. Having obesity induced by other endocrine disorders (e.g., Cushing's syndrome, acromegaly, undertreated hypothyroidism) or diagnosed with a monogenic or syndromic form of obesity (i.e., melanocyte-stimulating hormone 4 receptor deficiency or Pu-Wei syndrome).

[0882] v. Having a history or diagnosis of active or unstable major depressive disorder within two years after the screening visit, or anyHistory / diagnosis of other severe mental illnesses (e.g., schizophrenia, bipolar disorder, eating disorders, other severe mood, anxiety, or hyperactivity disorders). Note: Participants whose disease status is considered stable and who are expected to remain stable throughout the study are considered for inclusion only if they have been adequately controlled for ≥6 months with a stable dose of a selective serotonin reuptake inhibitor (other than paroxetine) prior to the screening visit and are expected to continue to be enrolled at the same dose throughout the study. Participants who maintain the use of other types of antidepressants / mood stabilizers are excluded from this study because many antidepressants / mood stabilizers are associated with weight changes.

[0883] w. Patient Health Questionnaire-9 (PHQ-9) score ≥15 at the screening visit or on Day 1.

[0884] x. History of any lifetime suicide attempt or suicidal behavior within 30 days prior to the screening visit.

[0885] y. Suicidal ideation assessed on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit or on day 1, and identified as:

[0886] i. Yes to question 4 (active suicidal ideation with some intention to act, without a specific plan), or

[0887] ii. Yes to question 5 (active suicidal ideation with a specific plan and intention) in the “Suicidal Ideation” section of the C-SSRS, or as stated on page 57 / 65 of the instruction manual, 60 CN 121398835 A

[0888] iii. Yes to any suicide-related behavior (actual attempt, interrupted attempt, discontinued attempt, preparation for action or behavior) in the “Suicidal Behavior” section of the C-SSRS, and

[0889] iv. Having the idea or behavior within the past month.

[0890] z. Having any blood condition that may interfere with HbA1c measurement (e.g., hemolytic anemia, sickle cell disease, other hemoglobinopathies).

[0891] aa. Having a family or personal history of medullary thyroid carcinoma, or a genetic predisposition to medullary thyroid carcinoma (i.e., thyroid C-cell hyperplasia or multiple endocrine neoplasia type 2A or 2B).

[0892] bb. Having an active or untreated malignancy prior to the screening visit, or having been in remission for <5 years from a clinically significant malignancy (excluding basal cell or squamous cell skin cancer, cervical cancer in situ, or prostate cancer in situ) prior to screening.

[0893] cc. Having received an organ transplant or awaiting an organ transplant (corneal transplantation may be permitted).

[0894] dd. Having any major medical and / or psychiatric conditions not specified above that the investigator believes would interfere with study evaluation, study completion, or safe treatment.

[0895] ee. History of atopic (severe or multiple anaphylaxis) or clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe hypersensitivity.

[0896] ff. History of alcohol addiction or tendency to abuse alcohol, as determined by the investigator, and / or an Alcohol Use Disorder Identification Test (AUDIT) score >14 during the screening visit.

[0897] gg. History of use of known abused substances within 12 months of the screening visit and / or a positive drug use test at the screening visit; and / or a history of use of cannabis or any other cannabis-related products within three months of the screening visit, and unwillingness to abstain from such products during the trial. Participants must also avoid the use of cannabidiol oil throughout the study duration.

[0898] hh. Screening visit and day 1 electrocardiogram (ECG) results:

[0899] i. Indications of active heart disease or clinically significant variability / abnormality as determined by the investigator that may interfere with the interpretation of ECG changes during the study

[0900] ii. Corrected QT (QTc; Fridericia) interval ≥ 450 ms for male participants and ≥ 470 ms for female participants, or

[0901] iii. Resting heart rate < 45 bpm or > 100 bpm; or

[0902] iv. Any other significant pathological rhythm; participants with first-degree conduction block are permitted to enroll.

[0903] ii. Any of the following results present during the screening period:

[0904] i. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) > 5.0 × the upper limit of normal (ULN) of the reference range

[0905] ii. Alkaline phosphatase > 2.0 × ULN of the reference range

[0906] iii. Total bilirubin > 1.5 × ULN of the reference range

[0907] iv. Amylase or lipase > 3 × ULN of the reference range

[0908] v. Calcitonin ≥ 20 ng / L (if eGFR ≥ 60 mL / min / 1.73 m2) or ≥ 35 ng / L (if eGFR < 60 mL / min / 1.73 m2)

[0909] jj. As per the 2021 Chronic Kidney Disease Epidemiology (CKD EPI) The estimated glomerular filtration rate (eGFR) obtained from the creatinine equation is <45 mL / min / 1.73 m2

[0910] kk. Fasting plasma triglycerides ≥500 mg / dL. Instructions for use, pages 58 / 65, 61 CN 121398835 A

[0911] ll. Acute or chronic viral hepatitis, based on hepatitis B surface antigen or hepatitis C virus.The presence of RNA was confirmed

[0912] mm. Currently receiving or within six months prior to the screening visit, or planning to receive any treatment that may lead to weight gain during the study. These treatments include, but are not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and testosterone preparations.

[0913] nn. Starting or significantly changing the dose of antihyperlipidemia medication within one month prior to the screening visit.

[0914] oo. Currently receiving or having received chronic (continuous >14 days) systemic glucocorticoid therapy within three months prior to the screening visit; or having evidence of a significant active autoimmune abnormality (e.g., lupus or rheumatoid arthritis) within three months prior to the screening visit or which the investigator deems necessary or likely to require concurrent systemic glucocorticoid therapy during the study.

[0915] Test Product, Dosage, and Administration

[0916] CT-388 20 mg / mL injection and placebo will be provided in 1.0 mL vials. CT-388 will be administered as a single SC injection via syringe.

[0917] Due to the nature of the study drug formulation, participants are not permitted to administer the study drug at any time during the study period. Therefore, throughout the study period, participants will be required to come to the research center / clinic for administration whenever possible, at approximately the same time of day and the same day of week. The study drug will be administered subcutaneously to the abdomen as an SC injection by a qualified researcher. If applicable, home care visits may also be used to administer the study drug to participants weekly.

[0918] Duration of Treatment

[0919] The total duration of individual participation will be approximately 58 weeks, including a five-week screening period (screening: day -35 to day -15 and a two-week introductory period [day -14 to day -1]), a 48-week treatment period (day 1 to at most week 48), and a five-week safety follow-up period (week 48 to week 53).

[0920] Efficacy Endpoints

[0921] The primary efficacy endpoints are the percentage change in body weight from baseline to week 48 and the change in HbA1c from baseline to week 48.

[0922] The key secondary efficacy endpoints were a weight loss of ≥5% (yes / no) from baseline to week 48 and a reduction in HbA1c to ≤7% (yes / no) from baseline to week 48.

[0923] Other secondary efficacy endpoints were

[0924] a. percentage change in weight from baseline to week 28

[0925] b. a weight loss of ≥10% (yes / no) from baseline to week 48

[0926] c. a weight loss of ≥15% (yes / no) from baseline to week 48

[0927] d. a weight loss of ≥20% (yes / no) from baseline to week 48

[0928] e. a weight loss of ≥25% (yes / no) from baseline to week 48

[0929] f. Absolute change in weight from baseline to week 28 and week 48 (kg)

[0930] g. Percentage change in weight by obesity level from baseline to week 28 and week 48

[0931] h. Change in HbA1c from baseline to week 12, week 28, and week 36

[0932] i. Change in HbA1c by obesity level from baseline to week 12, week 28, week 36, and week 48

[0933] j. HbA1c ≤ 6.5% at week 12, week 28, week 36, and week 48 (Yes / No)

[0934] k. HbA1c < 5.7% at week 12, week 28, week 36, and week 48 (Yes / No) Instructions for Use 59 / 65 pages 62 CN 121398835 A

[0935] l. Changes in 7-point SMBG characteristics at weeks 12, 28, 36, and 48

[0936] m. Percentage of participants who achieved HbA1c ≤ 6.5% and weight loss ≥ 10% at weeks 28 and 48

[0937] n. Percentage of participants who achieved HbA1c < 7% and weight loss ≥ 5% at weeks 28 and 48

[0938] o. Changes in weight-related parameters from baseline to week 48 as listed below:

[0939] i. BMI (kg / m2)

[0940] ii. Waist circumference (cm), hip circumference (cm), and waist-to-hip ratio

[0941] iii. Waist-to-height ratio

[0942] p. Glucose metabolism markers from baseline to weeks 12, 28, 36, and 48 Changes at week 36 and week 48:

[0943] i. Fasting blood glucose

[0944] ii. Fasting insulin

[0945] iii. Fasting C-peptide

[0946] iv. Fasting homeostasis model assessment for insulin resistance (HOMA-IR)

[0947] v. Quantitative insulin sensitivity test index (QUICKI)

[0948] The pharmacokinetic endpoints were CT-388 PK and metabolite concentration.

[0949] The safety endpoints were:

[0950] a. The number of participants who experienced ≥1 treatment-associated adverse event (TEAE) or any serious adverse event (SAE), adverse event of particular concern (AE), or AE leading to discontinuation of the study drug

[0951] b. TEAEs occurring in >10% of the randomized participants

[0952] c. The number of participants with a history of hypoglycemia (Section 10.3) (Levels 1, 2, and 3, according to ADA)2024)

[0953] d. Number of participants with severe persistent hyperglycemia

[0954] e. Percentage of participants requiring rescue therapy for T2DM management

[0955] f. Changes in C-SSRS and PHQ-9 from baseline

[0956] g. Changes in safety laboratory values, vital signs, and ECG

[0957] Use of antihyperglycemic agents

[0958] Randomized subjects are expected to continue taking antihyperglycemic agents at the same doses as at randomization.

[0959] Eligible participants will manage their T2DM with diet and exercise alone, or with metformin or metformin with or without an SGLT-2 inhibitor for three months.

[0960] During the study, only new antihyperglycemic agents other than the study drug or the drug prescribed at randomization will be permitted as rescue therapy for severe persistent hyperglycemia.

[0961] Dietary and Exercise Guidance

[0962] In accordance with local standards, all randomized participants in this study will receive lifestyle management guidance monthly and at least every 12 weeks during the study period from a dietitian or an equivalently qualified representative, either during scheduled visits or by telephone (where appropriate). The dietary and exercise goals identified during the lifestyle guidance, as well as the importance of adhering to the lifestyle components of the trial, will be reinforced by the researchers at each contact. Participants will be instructed on how to record their physical activity and food intake in a paper diary provided by the study to facilitate review and to provide appropriate guidance during their study visits.

[0963] Dietary guidance will include advice on healthy food choices and will focus on intake using a low-calorie diet, as per page 60 / 65 of CN 121398835 A, with the following macronutrient composition:

[0964] a. Up to 25% of energy from fat

[0965] b. Approximately 25% of energy from protein

[0966] c. Approximately 50% of energy from carbohydrates

[0967] d. An energy deficit of approximately 500 kcal / day is recommended compared to the participant's estimated total energy expenditure.

[0968] Total energy expenditure will be calculated using the weight planner from the National Institute of Diabetes, Digestive and Kidney Diseases, taking into account the participant's weight and physical activity level.

[0969] Participants with significantly suppressed appetite must be advised to consume at least 900 kcal / day, with an emphasis on adequate protein intake; high-protein guarantee / enhanced dietary alternatives may also be provided.

[0970] Regular physical activity is encouraged (150 minutes of physical activity per week, i.e., walking).

[0971] A low-calorie diet should be continued during randomization and throughout the treatment period.

[0972] If a BMI ≤22 is achieved...If the energy intake is calculated in kg / m2, the recommended energy intake should be recalculated for the remainder of the trial period, with no kilocalorie deficit.

[0973] This guideline should be considered as a recommendation and may be modified as needed by the participants.

[0974] To encourage adherence to this guideline, it is recommended to complete a three-day diet and exercise diary before each counseling visit. A mobile application or paper diary may be used. During each visit, the participant’s diet will be reviewed and maximum adherence advice will be provided as needed.

[0975] Patient Health Questionnaire-9

[0976] The PHQ-9 is a tool for assessing the severity of depression. Participants will answer each of the nine questions on a scale of 0 to +3, where 0 indicates no depression at all, +1 indicates several days, +2 indicates more than half the days, and +3 indicates almost every day. The scores are summed: 1 to 4 indicate very mild depression, 5 to 9 indicate mild depression, 10 to 14 indicate moderate depression, 15 to 19 indicate moderate to severe depression, and 20 to 27 indicate severe depression.

[0977] Columbia Suicide Severity Rating Scale

[0978] The C-SSRS is a tool for assessing the severity of suicidal ideation and behavior.

[0979] Weight and Body Mass Index

[0980] Weight measurements should be performed in a consistent manner, using a calibrated electronic scale capable of measuring weight in kilograms (kg) to one decimal place.

[0981] Weight measurements should be performed by qualified personnel who are adequately trained for the research procedures.

[0982] All weights of a given participant should be measured using the same scale at approximately the same time in the morning after the bladder has been emptied.

[0983] Weight must be measured after fasting for ≥8 hours. If participants are not fasting, they should attend another visit within the permitted visit window to measure their fasting weight.

[0984] BMI will be calculated using the height measured at baseline (entry visit) and the most recent weight measurement.

[0985] Waist and Hip Circumference

[0986] Waist circumference should be measured in the horizontal plane and at the midpoint between the lower edge of the last palpable rib and the top of the iliac crest.

[0987] Measurements should be taken at the end of a normal exhalation using a non-stretchable measuring tape. The measuring tape should be laid flat on the skin without compressing the soft tissue.

[0988] Waist circumference should be measured twice, and the results should be rounded to the nearest 0.5 cm. The measuring tape should be removed between measurements. The average of the two measurements should be recorded in the eCRF. If the difference between the two measurements exceeds 1 cm, the measurement results of Group A on pages 61 / 65 of this instruction manual (CN 121398835 A) should be discarded and the measurements repeated twice.

[0989] Vital signs

[0990] Vital signs, including temperature, blood pressure, heart rate, and respiratory rate, will be measured at each study visit. Vital signs will be measured after the participant has rested for ≥5 minutes in a sitting, supine, or semi-recumbent position.

[0991] For each parameter (including heart rate), three measurements will be taken using the same arm, preferably the non-dominant arm, with records taken ≥1 minute apart. Blood pressure must be measured using an automated blood pressure monitor if possible. If blood pressure and pulse are measured separately, the pulse should be measured before the blood pressure measurement. If the pulse cannot be measured using an automated blood pressure monitor, the radial artery should be used.

[0992] Participants will be reminded to avoid caffeine, smoking, and physical activity within 1 hour prior to the measurement of vital signs. The average of the three measurements will be entered into the eCRF.

[0993] Self-monitoring of blood glucose

[0994] Participants will be instructed to test their fasting blood glucose using the study-provided blood glucose meter, and to do so at least three times a week and as needed based on symptoms.

[0995] Self-monitoring of blood glucose using the study-provided blood glucose meter will begin at induction and will continue throughout the study.

[0996] At specific time points during the study, a 7-point SMBG curve consisting of measurements will be obtained before each meal, approximately two hours after each meal, and at bedtime one week prior to the designated planned clinic visit. The complete 7-point curve must be collected within one day. If a participant does not complete the entire curve within one day, all seven points must be collected the following day.

[0997] Clinical Laboratory Assessment

[0998] Blood and urine samples will be collected for hematological, biochemical, and other clinical laboratory tests.

[0999] Of particular importance, glucose and HbA1c samples must be collected to monitor safety and determine the purpose of the study.

[1000] Various biomarkers considered to be affected by obesity and its comorbidities, as well as biomarkers affecting cardiovascular risk factors, will be assessed, and blood samples will be collected for assessment.

[1001] In addition to these biomarkers, other relevant biomarkers may emerge during the study. If this occurs, these other biomarkers may also be assessed.

[1002] All laboratory assessments will be conducted centrally. In emergency situations, local assessment of selected laboratory tests may be necessary for emergency decision-making; however, it is strongly recommended that investigators collect duplicate laboratory samples at the time of local collection and transport the duplicate samples to a central laboratory for analysis. If participants reside in remote areas, local laboratory tests may be performed for selected visits as a last resort.

[1003] Magnetic Resonance Imaging

[1004] MRI will be performed at selected research centers. All participants at these research centers, randomly assigned to groups, will participate in MRI data collection.

[1005] MRI examinations will include body composition (lean body mass / volume, visceral and subcutaneous adipose tissue volume) and muscle composition.Assessment of (thigh muscle volume, contractile thigh muscle volume, intramuscular fat fraction and volume). Liver and pancreatic fat fraction and liver, pancreas and spleen volumes will also be assessed. Cerebral perfusion will be studied via arterial spin labeling.

[1006] No contrast agents will be administered for any MRI assessment. Participants are required to fast for 4 hours prior to MRI and avoid hemodynamic stimulants (e.g., caffeinated beverages and medications such as acetazolamide). Smoking is also prohibited.

[1007] Study Drug Package Insert 62 / 65 pages 65 CN 121398835 A

[1008] CT-388 injection (reconstituted with sodium phosphate buffer at pH 7.0 and mannitol to a concentration of 20 mg / mL) or CT-388 placebo is provided in clear liquid form in glass vials for SC administration. The CT-388 placebo is the same formulation without the active CT-388 component. Each vial contains 1.0 mL of single-use liquid. All excipients are Pharmacopoeia compliant. The drug is manufactured, packaged, and labeled in accordance with current Good Manufacturing Practices (GMP).

[1009] The study drug should be frozen and stored in a safe, controlled location at -20°C.

[1010] The study drug will be administered subcutaneously via the abdomen as a SC injection only by qualified researchers. Participants are not permitted to administer the study drug themselves during the study. Therefore, participants are expected to visit the research center / clinic for drug administration whenever possible.

[1011] Throughout the study, abdominal injections of the study drug should be administered at approximately the same time and date of the week whenever possible.

[1012] If applicable, the study drug may also be administered weekly via home care visits. This dose will be administered as a single SC injection.

[1013] The last time point to escalate the dose to the randomized target dose is week 27. The final dose will be administered in week 47.

[1014] Dosage Titration

[1015] The dose for each participant in the low-to-high dose treatment of CT-388 will be escalated as shown in Figure 21. Participants experiencing GI-related symptoms should be managed as shown in Figure 20.

[1016] Participants must tolerate at least 4 mg to continue using the study drug. Dose reductions below 4 mg are not permitted. Participants who are still intolerant to a 4 mg dose despite symptom relief measures or dose adjustments (including medication holidays) will discontinue the study drug.

[1017] Dose escalation may occur at or after the designated escalation time, but not before the designated escalation time.

[1018] The last escalation / re-enhancement time point is week 27.

[1019] Participants must tolerate at least 4 mg to continue using the study drug. Dose reductions below 4 mg are not permitted.Participants who are intolerant to the 4 mg dose despite symptom relief measures or dose adjustments (including medication holidays) will discontinue the study drug.

[1020] Adverse Events

[1021] An AE is any adverse and unexpected sign (including abnormal laboratory findings), symptom, or illness that is temporarily associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.

[1022] A TEAE is defined as an AE that worsens or begins at or after the first administration of the study drug. All AEs will be recorded throughout the study period (i.e., from screening to the last follow-up visit or 45 days after the last administration of the study drug, whichever is later), regardless of their severity or how they are identified (e.g., voluntary, induced, or recorded during a physical examination).

[1023] Participants' AEs will be tracked for resolution by asking them if they have a persistent AE, up to the earlier of the AE resolution or the last study visit. At the last study visit, all AEs must have an outcome (resolved or ongoing) that will be recorded in the participant's eCRF.

[1024] Pregnancy itself is not considered an AE or SAE unless delivery results in a congenital abnormality / birth defect or the study drug is suspected of interfering with the effectiveness of the contraceptive drug or method. Nevertheless, any pregnancy must be reported to the clinical safety department within 24 hours of being informed. Once pregnancy is confirmed, administration of the study drug will be discontinued. Pregnancy will be followed up to term and / or outcome and that outcome must be reported to the pharmacovigilance team. If a pregnancy outcome meets the criteria for immediate classification as an SAE (i.e., postpartum complications, spontaneous abortion, stillbirth, neonatal death, or congenital abnormality, see page 63 / 65 of the instruction manual, CN 121398835 A), the investigator should follow the procedures for reporting SAEs.

[1025] The investigator will score the severity / intensity of each AE. The investigator may refer to the National Cancer Institute – Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The CTCAE is graded from 1 to 5, with a unique clinical description of the severity of each AE. A general grading (severity / intensity) scale for those events not specifically listed is provided at the beginning of the CTCAE reference document. If the severity / intensity of a particular AE is not specified, the investigator should revert to the general scale and use their best medical judgment.

[1026] The five general grades are:

[1027] a. Grade 1: Mild

[1028] b. Grade 2: Moderate

[1029] c. Grade 3: Severe

[1030] d. Grade 4: Life-threatening or disabling

[1031] e. Grade 5: Death related to the AE

[1032] The term “nausea” is used only when a participant specifically reports feeling nauseous and having an urge to vomit to describe an AE. The term “diarrhea” is used only when a participant specifically reports having three or more watery or liquid stools per day to describe an AE. The Bristol Stool Chart can be used as a guide to characterize diarrhea.

[1033] Researchers will use a five-class system (unrelated, unlikely, likely, probable, and certain) to determine the relationship between an AE and the study drug (including placebo) in a blinded state.

[1034] A serious adverse event (SAE) is any adverse medical event that occurs at any dose and results in any of the following outcomes:

[1035] a. death

[1036] b. a life-threatening event (i.e., that, in the researcher’s view, puts the participant at risk of immediate death)

[1037] c. hospitalization or prolongation of current hospitalization

[1038] d. any admission or hospitalization involving an overnight stay.

[1039] e. According to this standard, an emergency room or emergency care visit that does not involve formal hospitalization will not be recorded as an SAE, nor will a surgical hospitalization arranged or planned prior to the signing of informed consent be recorded as an SAE. However, unexpected complications and / or prolonged hospitalizations occurring during elective surgery should be recorded as AEs and their severity assessed.

[1040] f. Persistent or severe loss of capacity or serious impairment of the ability to perform normal life functions

[1041] g. Congenital abnormalities / birth defects

[1042] Important medical events that may not result in death, are life-threatening, or require hospitalization may be considered SAEs if, based on appropriate medical judgment, they may endanger the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

[1043] An unexpected adverse drug event is any adverse drug event whose specificity or severity is inconsistent with the current investigator's manual. Unexpected and related SAEs should be reported to regulatory agencies. Investigators will report reportable SAEs to the sponsor and, where necessary, to the responsible EC or IRB. To report an SAE, research center staff should complete an SAE form and submit it to the sponsor's representative within 24 hours of becoming aware of the event.

[1044] Laboratory Abnormal Results and Other Abnormal Results

[1045] Laboratory abnormal results and other abnormal study results (e.g., related to ECG curves) should not be reported as AEs unless they are associated with clinical signs and symptoms, lead to treatment discontinuation, or are deemed by the investigator to have other medical significance. If the abnormality meets these criteria, the identified medical condition (e.g., anemia, elevated ALT) must be reported as an AE, not the abnormal value itself. The investigator will refer to the National Cancer Institute – Common Terminology for Adverse Events.(CTCAE) version 5.0 rates the severity of abnormal laboratory results.

[1046] Precautions

[1047] Participants experiencing GI symptoms (e.g., nausea, vomiting, or diarrhea) at any time during the study should first receive guidance on dietary behaviors that may help alleviate nausea and vomiting (e.g., reducing the size of each meal, dividing three meals a day into four or more meals, and stopping eating when feeling full).

[1048] If symptoms persist, the investigator should, at their discretion, prescribe symptomatic medications (e.g., antiemetics or antidiarrheals) to the participant (Figure 20).

[1049] Indigestion or bloating symptoms during the study can be treated symptomatically with medications that do not increase the QTc interval (e.g., calcium carbonate, bismuth subsalicylate). H2 receptor antagonists (e.g., famotidine, known to prolong the QTc interval) are contraindicated.

[1050] Nausea and / or vomiting during this study can be treated with antiemetics (such as ondansetron), but should not be used prophylactically. Smaller portions and other conservative measures should be encouraged to alleviate nausea / vomiting, which may be seen as a result of delayed / slow gastric emptying, a known PD effect of GLP-1 and incretin-based drug classes.

[1051] Constipation should initially be treated with hydration, fiber, and smaller portions of food. If medication is needed, Coloxyl with senna or Movicol, Metamucil, Colace, or Dulcolax or regional analogues are recommended.

[1052] Loperamide may be used for a short period (1 to 2 days) only if diarrhea is considered severe and significantly affects the participant's ability to function. Opioid-based drugs are generally prohibited during this study period because they have a recognized effect on reducing GI dynamics, which may further exacerbate GI-related adverse events.

[1053] Temporary interruption of a dose of study drug due to GI symptoms is permitted, provided that the participant has taken the dose for the last 3 weeks. The study treatment should be restarted immediately at the specified dose, whether alone or in combination with symptomatic medications, which may also be used to control symptoms.

[1054] If, despite the above measures, intolerable GI symptoms (e.g., nausea, vomiting, or diarrhea) persist, the investigator may consider restarting the next lowest maintenance dose of the study drug in a blinded manner (e.g., from 24 mg to 20 mg, from 20 mg to 16 mg, from 16 mg to 12 mg, from 12 mg to 8 mg, or from 8 mg to 4 mg) (Figure 20). If, despite symptomatic treatment, temporary interruption of the drug, and resumption with a lower dose of the study drug, intolerable GI persists...If symptoms appear, the study drug should be discontinued. All participants who discontinue the study drug should continue to attend planned study visits. Instruction manual page 65 / 65, page 68, CN 121398835 A, Figure 1A; Instruction manual figure 1 / 29 page, page 69, CN 121398835 A, Figure 1B; Instruction manual figure 2 / 29 page, page 70, CN 121398835 A, Figure 1C; Instruction manual figure 3 / 29 page, page 71, CN 121398835 A, Figure 2A; Instruction manual figure 4 / 29 page, page 72, CN 121398835 A, Figure 2B; Instruction manual figure 5 / 29 page, page 73, CN 121398835 A, Figure 3; Instruction manual figure 6 / 29 page, page 74, CN 121398835 A, Figure 4; Instruction manual figure 7 / 29 page, page 75, CN 121398835 A, Figure 5; Instruction manual figure 8 / 29 page, page 76, CN 121398835 A, Figure 5 (continued); Instruction manual figure 9 / 29 page, page 77, CN 121398835 A. Figure 6. Instruction manual illustration, page 10 / 29, 78 CN 121398835 A. Figure 6 (continued). Instruction manual illustration, page 11 / 29, 79 CN 121398835 A. Figure 7A. Instruction manual illustration, page 12 / 29, 80 CN 121398835 A. Figure 7B. Instruction manual illustration, page 13 / 29, 81 CN 121398835 A. Figure 8. Instruction manual illustration, page 14 / 29, 82 CN 121398835 A. Figure 9. Instruction manual illustration, page 15 / 29, 83 CN 121398835 A. Figure 10. Instruction manual illustration, page 16 / 29, 84 CN 121398835 A. Figure 11. Instruction manual illustration, page 17 / 29, 85 CN 121398835 A. Figure 12. Instruction manual illustration, page 18 / 29, 86 CN 121398835 A. Figure 13. Instruction manual illustration, page 19 / 29. Page 87 CN 121398835 A Figure 14 Instruction Manual Drawing 20 / 29 Page 88 CN 121398835 A Figure 15 Instruction Manual Drawing 21 / 29 Page 89 CN 121398835 A Figure 16 Instruction Manual Drawing 22 / 29 Page 90 CN 121398835 A Figure 17A Instruction Manual Drawing 23 / 29 Page 91 CN 121398835 A Figure 17B Instruction Manual DrawingPages 24 / 29, 92 CN 121398835 A, Figure 18, Instruction Manual Drawing; Pages 25 / 29, 93 CN 121398835 A, Figure 19, Instruction Manual Drawing; Pages 26 / 29, 94 CN 121398835 A, Figure 20, Instruction Manual Drawing; Pages 27 / 29, 95 CN 121398835 A, Figure 20 (continued), Instruction Manual Drawing; Pages 28 / 29, 96 CN 121398835 A, Figure 21, Instruction Manual Drawing; Pages 29 / 29, 97 CN 121398835 A

Claims

1. A method of managing body weight, improving glycemic control and / or increasing insulin sensitivity in an overweight or obese adult patient in need thereof, the method comprising administering to the patient by subcutaneous injection a compound of Formula I or a pharmaceutically acceptable salt or ester thereof: (Formula I) [SEQ ID NO: 1], wherein the compound is administered at a weight agnostic dose of about 2.0 mg to about 25 mg.

3. The method of claim 1, wherein the patient is obese.

4. The method of claim 3, wherein the patient does not have type 2 diabetes, or is pre-diabetic.

5. The method of claim 3, wherein the patient has type 2 diabetes.

6. The method of any one of claims 1 to 5, wherein the patient has one or more weight related comorbidities, optionally pre-diabetes, hypertension or dyslipidemia.

7. The method of any one of claims 1 to 6, wherein the administering step is repeated once a week, once every two weeks, once every four weeks or once a month.

8. The method of any one of the preceding claims, wherein the dose is about 5, 6, 7.5, 8, 12, 16, 17, 22 or 24 mg.

2. The method of claim 1, wherein the patient has a BMI of > 25 kg / m 2 , > 27 kg / m 2 , > 30 kg / m 2 , > 35 kg / m 2 , or > 40 kg / m 2 .

9. The method of any one of the preceding claims, wherein the dose is titrated up over a period of 3 weeks to 30 weeks.

10. The method of claim 9, wherein the starting dose for the titration is about 5 mg or about 8 mg.

11. The method of claim 10, wherein the maximum dose for the titration is about 22 mg or 24 mg.

12. The method of any one of the preceding claims, wherein the patient receives an additional therapy for overweight or obesity, optionally wherein the additional therapy is a dietary therapy or an exercise therapy.

13. The method of any one of the preceding claims, wherein administration of the compound results in a reduction in visceral fat and / or HbAlc levels in the patient.

14. A compound for use in a method according to any one of claims 1 to 13, wherein the compound is a compound of Formula I or a pharmaceutically acceptable salt or ester thereof: (Formula I) [SEQ ID NO: 1].

15. Use of a compound for the manufacture of a medicament for use in a method according to any one of claims 1 to 13, wherein the compound is a compound of Formula I or a pharmaceutically acceptable salt or ester thereof: (Formula I) [SEQ ID NO: 1].

16. An article of manufacture for use in a method according to any one of claims 1 to 13, wherein the article of manufacture comprises one or more units of the dose.

17. The article of manufacture of claim 16, wherein the article of manufacture comprises a syringe or an injector, optionally a disposable syringe or an injector. ​ ​ ​ ​ ​ ​ ​ ​